EASL Clinical Practice Guidelines

References

[1]Calne, R.Y., Williams, R., Dawson, J.L., Ansell, I.D., Evans, D.B., Flute, P.T. et al. Liver transplantation in man. II. A report of two orthotopic liver transplants in adult recipients. Br Med J. 1968; 4: 541–546
PubMed

[2]Starzl, T.E., Marchioro, T.L., Porter, K.A., and Brettschneider, L. Homotransplantation of the liver. Transplantation. 1967; 5: 790–803
CrossRef | PubMed

[3]Adam, R., Karam, V., Delvart, V., O’Grady, J., Mirza, D., Klempnauer, J. et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57: 675–688
Abstract | Full Text | Full Text PDF | PubMed | Scopus (91)

[4]Dutkowski, P., De Rougemont, O., Mullhaupt, B., and Clavien, P.A. Current and future trends in liver transplantation in Europe. Gastroenterology. 2010; 138: 802–809 (e1–e4)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (34)

[5]Dutkowski, P., Linecker, M., DeOliveira, M.L., Mullhaupt, B., and Clavien, P.A. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015; 148: 307–323
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[6]Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924–926
CrossRef | PubMed

[7]Lee, W.M., Squires, R.H. Jr., Nyberg, S.L., Doo, E., and Hoofnagle, J.H. Acute liver failure: summary of a workshop. Hepatology. 2008; 47: 1401–1415
CrossRef | PubMed | Scopus (268)

[8]Bernal, W. Changing patterns of causation and the use of transplantation in the United kingdom. Semin Liver Dis. 2003; 23: 227–237
CrossRef | PubMed | Scopus (98)

[9]Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P. et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124: 91–96
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1090)

[10]Malinchoc, M., Kamath, P.S., Gordon, F.D., Peine, C.J., Rank, J., and ter Borg, P.C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000; 31: 864–871
CrossRef | PubMed

[11]Merion, R.M., Schaubel, D.E., Dykstra, D.M., Freeman, R.B., Port, F.K., and Wolfe, R.A. The survival benefit of liver transplantation. Am J Transplant. 2005; 5: 307–313
CrossRef | PubMed | Scopus (394)

[12]Habib, S., Berk, B., Chang, C.C., Demetris, A.J., Fontes, P., Dvorchik, I. et al. MELD and prediction of post-liver transplantation survival. Liver Transpl. 2006; 12: 440–447
CrossRef | PubMed | Scopus (108)

[13]Freeman, R.B. Jr., Gish, R.G., Harper, A., Davis, G.L., Vierling, J., Lieblein, L. et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006; 12: S128–S136
CrossRef | PubMed | Scopus (67)

[14]Kim, W.R., Biggins, S.W., Kremers, W.K., Wiesner, R.H., Kamath, P.S., Benson, J.T. et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008; 359: 1018–1026
CrossRef | PubMed | Scopus (351)

[15]Huo, T.I., Wu, J.C., Lin, H.C., Lee, F.Y., Hou, M.C., Lee, P.C. et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol. 2005; 42: 826–832
Abstract | Full Text | Full Text PDF | PubMed | Scopus (93)

[16]Merion, R.M., Wolfe, R.A., Dykstra, D.M., Leichtman, A.B., Gillespie, B., and Held, P.J. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003; 9: 12–18
CrossRef | PubMed | Scopus (128)

[17]EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol. 2009; 50: 227–242
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1232)

[18]Burra, P., Germani, G., Adam, R., Karam, V., Marzano, A., Lampertico, P. et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013; 58: 287–296
Abstract | Full Text | Full Text PDF | PubMed | Scopus (17)

[19]Schiff, E., Lai, C.L., Hadziyannis, S., Neuhaus, P., Terrault, N., Colombo, M. et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13: 349–360
CrossRef | PubMed | Scopus (195)

[20]Liaw, Y.F., Raptopoulou-Gigi, M., Cheinquer, H., Sarin, S.K., Tanwandee, T., Leung, N. et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011; 54: 91–100
CrossRef | PubMed | Scopus (102)

[21]Liaw, Y.F., Sheen, I.S., Lee, C.M., Akarca, U.S., Papatheodoridis, G.V., Suet-Hing Wong, F. et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53: 62–72
CrossRef | PubMed | Scopus (162)

[22]Shim, J.H., Lee, H.C., Kim, K.M., Lim, Y.S., Chung, Y.H., Lee, Y.S. et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52: 176–182
Abstract | Full Text | Full Text PDF | PubMed | Scopus (122)

[23]Lange, C.M., Bojunga, J., Hofmann, W.P., Wunder, K., Mihm, U., Zeuzem, S. et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50: 2001–2006
CrossRef | PubMed | Scopus (142)

[24]Kapoor, D., Guptan, R.C., Wakil, S.M., Kazim, S.N., Kaul, R., Agarwal, S.R. et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33: 308–312
Abstract | Full Text | Full Text PDF | PubMed | Scopus (149)

[25]Tillmann, H.L., Hadem, J., Leifeld, L., Zachou, K., Canbay, A., Eisenbach, C. et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006; 13: 256–263
CrossRef | PubMed | Scopus (127)

[26]Roche, B. and Samuel, D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012; 32: 245–255
CrossRef | PubMed

[27]Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49: 274–287
Abstract | Full Text | Full Text PDF | PubMed | Scopus (198)

[28]Crespo, G., Marino, Z., Navasa, M., and Forns, X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383 (e1)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (69)

[29]Pawlotsky, J.M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 1176–1192
Abstract | Full Text | Full Text PDF | PubMed | Scopus (114)

[30]Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced disease. Gastroenterology. 2015; 149: 649–659
Abstract | Full Text | Full Text PDF | PubMed | Scopus (11)

[31]Carrion, J.A., Martinez-Bauer, E., Crespo, G., Ramirez, S., Perez-del-Pulgar, S., Garcia-Valdecasas, J.C. et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009; 50: 719–728
Abstract | Full Text | Full Text PDF | PubMed | Scopus (112)

[32]Everson, G.T., Terrault, N.A., Lok, A.S., Rodrigo del, R., Brown, R.S. Jr., Saab, S. et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013; 57: 1752–1762
CrossRef | PubMed | Scopus (52)

[33]Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417–2428
CrossRef | PubMed | Scopus (1109)

[34]Hezode, C., Fontaine, H., Dorival, C., Larrey, D., Zoulim, F., Canva, V. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013; 59: 434–441
Abstract | Full Text | Full Text PDF | PubMed | Scopus (243)

[35]Gambato, M., Lens, S., Navasa, M., and Forns, X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014; ([Epub ahead of print])

[36]Curry, M.P., Forns, X., Chung, R.T., Terrault, N., Brown, R.S., Fenkel, J.M. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015; 148: 100–107
Abstract | Full Text | Full Text PDF | PubMed | Scopus (45)

[37]Poordad, F., Hezode, C., Trinh, R., Kowdley, K.V., Zeuzem, S., Agarwal, K. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370: 1973–1982
CrossRef | PubMed | Scopus (193)

[38]Jensen, D.M., O’Leary, J.G., Pockros, P.J., Sherman, K.E., Kwo, P.Y., Mailliard, M.E. et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology. 2014; 60: 219A

[39]Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370: 211–221
CrossRef | PubMed | Scopus (313)

[40]<http://www.eltr.org>.[41]Burra, P., Senzolo, M., Adam, R., Delvart, V., Karam, V., Germani, G. et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010; 10: 138–148
http://www.eltr.org | CrossRef | PubMed | Scopus (96)

[42]Pfitzmann, R., Schwenzer, J., Rayes, N., Seehofer, D., Neuhaus, R., and Nussler, N.C. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007; 13: 197–205
CrossRef | PubMed | Scopus (109)

[43]Yates, W.R., Martin, M., LaBrecque, D., Hillebrand, D., Voigt, M., and Pfab, D. A model to examine the validity of the 6-month abstinence criterion for liver transplantation. Alcohol Clin Exp Res. 1998; 22: 513–517
CrossRef | PubMed

[44]Mathurin, P., Duchatelle, V., Ramond, M.J., Degott, C., Bedossa, P., Erlinger, S. et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996; 110: 1847–1853
Abstract | Full Text | Full Text PDF | PubMed | Scopus (171)

[45]Mathurin, P., O’Grady, J., Carithers, R.L., Phillips, M., Louvet, A., Mendenhall, C.L. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011; 60: 255–260
CrossRef | PubMed | Scopus (107)

[46]Louvet, A., Naveau, S., Abdelnour, M., Ramond, M.J., Diaz, E., Fartoux, L. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007; 45: 1348–1354
CrossRef | PubMed | Scopus (182)

[47]O’Shea, R.S., Dasarathy, S., and McCullough, A.J. Alcoholic liver disease. Hepatology. 2010; 51: 307–328
CrossRef | PubMed | Scopus (312)

[48]Mathurin, P., Moreno, C., Samuel, D., Dumortier, J., Salleron, J., Durand, F. et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365: 1790–1800
CrossRef | PubMed | Scopus (141)

[49]Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., and Dierkhising, R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011; 141: 1249–1253
Abstract | Full Text | Full Text PDF | PubMed | Scopus (208)

[50]Charlton, M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013; 18: 251–258
CrossRef | PubMed | Scopus (13)

[51]Dare, A.J., Plank, L.D., Phillips, A.R., Gane, E.J., Harrison, B., Orr, D. et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl. 2014; 20: 281–290
CrossRef | PubMed | Scopus (13)

[52]Hakeem, A.R., Cockbain, A.J., Raza, S.S., Pollard, S.G., Toogood, G.J., Attia, M.A. et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver Transpl. 2013; 19: 551–562
CrossRef | PubMed | Scopus (15)

[53]Rudic, J.S., Poropat, G., Krstic, M.N., Bjelakovic, G., and Gluud, C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012; 1: CD009145
PubMed

[54]Carbone, M. and Neuberger, J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol. 2011; 35: 446–454
CrossRef | PubMed | Scopus (22)

[55]Boberg, K.M. and Lind, G.E. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011; 25: 753–764
Abstract | Full Text | Full Text PDF | PubMed | Scopus (28)

[56]Ringe, B., Weimann, A., Lamesch, P., Nashan, B., and Pichlmayr, R. Liver transplantation as an option in patients with cholangiocellular and bile duct carcinoma. Cancer Treat Res. 1994; 69: 259–275
CrossRef | PubMed

[57]Singh, S., Loftus, E.V. Jr., and Talwalkar, J.A. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol. 2013; 108: 1417–1425
CrossRef | PubMed | Scopus (0)

[58]Manns, M.P., Czaja, A.J., Gorham, J.D., Krawitt, E.L., Mieli-Vergani, G., Vergani, D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51: 2193–2213
CrossRef | PubMed | Scopus (401)

[59]Ichai, P., Duclos-Vallee, J.C., Guettier, C., Hamida, S.B., Antonini, T., Delvart, V. et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007; 13: 996–1003
CrossRef | PubMed | Scopus (105)

[60]Fagiuoli, S., Daina, E., D’Antiga, L., Colledan, M., and Remuzzi, G. Monogenic diseases that can be cured by liver transplantation. J Hepatol. 2013; 59: 595–612
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[61]EASL Clinical Practice Guidelines. Wilson’s disease. J Hepatol. 2012; 56: 671–685
Abstract | Full Text | Full Text PDF | PubMed | Scopus (49)

[62]Lui, C.C., Chen, C.L., Cheng, Y.F., and Lee, T.Y. Recovery of neurological deficits in a case of Wilson’s disease after liver transplantation. Transplant Proc. 1998; 30: 3324–3325
Abstract | Full Text | Full Text PDF | PubMed | Scopus (20)

[63]Medici, V., Mirante, V.G., Fassati, L.R., Pompili, M., Forti, D., Del Gaudio, M. et al. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl. 2005; 11: 1056–1063
CrossRef | PubMed | Scopus (62)

[64]Niederau, C., Fischer, R., Sonnenberg, A., Stremmel, W., Trampisch, H.J., and Strohmeyer, G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985; 313: 1256–1262
CrossRef | PubMed

[65]Powell, L.W. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology. 1996; 110: 1304–1307
Abstract | Full Text | Full Text PDF | PubMed | Scopus (25)

[66]Kowdley, K.V., Brandhagen, D.J., Gish, R.G., Bass, N.M., Weinstein, J., Schilsky, M.L. et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005; 129: 494–503
Abstract | Full Text | Full Text PDF | PubMed | Scopus (60)

[67]Bobrowski, A.E. and Langman, C.B. The primary hyperoxalurias. Semin Nephrol. 2008; 28: 152–162
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[68]Watts, R.W. The clinical spectrum of the primary hyperoxalurias and their treatment. J Nephrol. 1998; 11: 4–7
PubMed

[69]Cochat, P., Fargue, S., and Harambat, J. Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant. 2010; 15: 590–593
CrossRef | PubMed | Scopus (11)

[70]Hoppe, B., Beck, B.B., and Milliner, D.S. The primary hyperoxalurias. Kidney Int. 2009; 75: 1264–1271
CrossRef | PubMed | Scopus (119)

[71]Yamashita, T., Ando, Y., Okamoto, S., Misumi, Y., Hirahara, T., Ueda, M. et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012; 78: 637–643
CrossRef | PubMed | Scopus (42)

[72]Herlenius, G., Wilczek, H.E., Larsson, M., and Ericzon, B.G. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004; 77: 64–71
CrossRef | PubMed | Scopus (163)

[73]Plante-Bordeneuve, V. and Said, G. Familial amyloid polyneuropathy. Lancet Neurol. 2011; 10: 1086–1097
Abstract | Full Text | Full Text PDF | PubMed | Scopus (126)

[74]Okamoto, S., Wixner, J., Obayashi, K., Ando, Y., Ericzon, B.G., Friman, S. et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl. 2009; 15: 1229–1235
CrossRef | PubMed | Scopus (53)

[75]Ohya, Y., Okamoto, S., Tasaki, M., Ueda, M., Jono, H., Obayashi, K. et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today. 2011; 41: 1211–1218
CrossRef | PubMed | Scopus (16)

[76]Gustafsson, S., Ihse, E., Henein, M.Y., Westermark, P., Lindqvist, P., and Suhr, O.B. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012; 93: 1017–1023
CrossRef | PubMed | Scopus (14)

[77]Adams, D., Lacroix, C., Antonini, T., Lozeron, P., Denier, C., Kreib, A.M. et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid. 2011; 18: 174–177
CrossRef | PubMed

[78]Antonini, T.M., Lozeron, P., Lacroix, C., Mincheva, Z., Durrbach, A., Slama, M. et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant. 2013; 13: 2734–2738
CrossRef | PubMed | Scopus (0)

[79]Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693–699
CrossRef | PubMed | Scopus (3533)

[80]Yao, F.Y., Ferrell, L., Bass, N.M., Watson, J.J., Bacchetti, P., Venook, A. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33: 1394–1403
CrossRef | PubMed | Scopus (1040)

[81]Vibert, E., Azoulay, D., Hoti, E., Iacopinelli, S., Samuel, D., Salloum, C. et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010; 10: 129–137
CrossRef | PubMed | Scopus (91)

[82]Duvoux, C., Roudot-Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T. et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012; 143: 986–994 (e3; quiz e14–e15)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (69)

[83]Clavien, P.A., Lesurtel, M., Bossuyt, P.M., Gores, G.J., Langer, B., and Perrier, A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012; 13: e11–e22
Abstract | Full Text | Full Text PDF | PubMed | Scopus (196)

[84]Aloia, T.A., Adam, R., Samuel, D., Azoulay, D., and Castaing, D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg. 2007; 11: 1328–1332
CrossRef | PubMed | Scopus (13)

[85]Llovet, J.M., Mas, X., Aponte, J.J., Fuster, J., Navasa, M., Christensen, E. et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002; 50: 123–128
CrossRef | PubMed

[86]Mergental, H. and Porte, R.J. Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int. 2010; 23: 662–667
CrossRef | PubMed | Scopus (16)

[87]Bridgewater, J., Galle, P.R., Khan, S.A., Llovet, J.M., Park, J.W., Patel, T. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60: 1268–1289
Abstract | Full Text | Full Text PDF | PubMed | Scopus (31)

[88]Rosen, C.B., Heimbach, J.K., and Gores, G.J. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010; 23: 692–697
CrossRef | PubMed | Scopus (74)

[89]Rana, A. and Hong, J.C. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012; 28: 258–265
CrossRef | PubMed | Scopus (9)

[90]Darwish Murad, S., Kim, W.R., Harnois, D.M., Douglas, D.D., Burton, J., Kulik, L.M. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012; 143: 88–98 (e3; quiz e14)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (96)

[91]Lerut, J.P., Orlando, G., Adam, R., Schiavo, M., Klempnauer, J., Mirza, D. et al. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg. 2007; 246: 949–957 (Discussion 57)
CrossRef | PubMed | Scopus (63)

[92]Hoti, E. and Adam, R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008; 21: 1107–1117
CrossRef | PubMed | Scopus (42)

[93]Hagness, M., Foss, A., Line, P.D., Scholz, T., Jorgensen, P.F., Fosby, B. et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013; 257: 800–806
CrossRef | PubMed | Scopus (22)

[94]Aduen, J.F., Sujay, B., Dickson, R.C., Heckman, M.G., Hewitt, W.R., Stapelfeldt, W.H. et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc. 2009; 84: 973–978
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[95]Cross, T.J., Antoniades, C.G., Muiesan, P., Al-Chalabi, T., Aluvihare, V., Agarwal, K. et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007; 13: 1382–1388
CrossRef | PubMed | Scopus (48)

[96]Garcia, C.E., Garcia, R.F., Mayer, A.D., and Neuberger, J. Liver transplantation in patients over sixty years of age. Transplantation. 2001; 72: 679–684
CrossRef | PubMed

[97]Moller, S. and Henriksen, J.H. Cirrhotic cardiomyopathy. J Hepatol. 2010; 53: 179–190
Abstract | Full Text | Full Text PDF | PubMed | Scopus (112)

[98]An, J., Shim, J.H., Kim, S.O., Lee, D., Kim, K.M., Lim, Y.S. et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation. 2014; 130: 1353–1362
CrossRef | PubMed | Scopus (6)

[99]Bernal, W., Martin-Mateos, R., Lipcsey, M., Tallis, C., Woodsford, K., McPhail, M.J. et al. Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease. Liver Transpl. 2014; 20: 54–62
CrossRef | PubMed | Scopus (8)

[100]Wray, C., Scovotti, J.C., Tobis, J., Niemann, C.U., Planinsic, R., Walia, A. et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transplant. 2013; 13: 184–191
CrossRef | PubMed | Scopus (9)

[101]Umeda, N. and Kamath, P.S. Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res. 2009; 39: 1020–1022
CrossRef | PubMed | Scopus (17)

[102]Koch, D.G. and Fallon, M.B. Hepatopulmonary syndrome. Curr Opin Gastroenterol. 2014; 30: 260–264
CrossRef | PubMed | Scopus (1)

[103]Arguedas, M.R., Abrams, G.A., Krowka, M.J., and Fallon, M.B. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology. 2003; 37: 192–197
CrossRef | PubMed | Scopus (219)

[104]Pastor, C.M. and Schiffer, E. Therapy Insight: hepatopulmonary syndrome and orthotopic liver transplantation. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 614–621
CrossRef | PubMed | Scopus (11)

[105]Ashfaq, M., Chinnakotla, S., Rogers, L., Ausloos, K., Saadeh, S., Klintmalm, G.B. et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007; 7: 1258–1264
CrossRef | PubMed | Scopus (74)

[106]Swanson, K.L., Wiesner, R.H., Nyberg, S.L., Rosen, C.B., and Krowka, M.J. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008; 8: 2445–2453
CrossRef | PubMed | Scopus (102)

[107]Hoeper, M.M., Krowka, M.J., and Strassburg, C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004; 363: 1461–1468
Abstract | Full Text | Full Text PDF | PubMed | Scopus (273)

[108]Fix, O.K., Bass, N.M., De Marco, T., and Merriman, R.B. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 2007; 13: 875–885
CrossRef | PubMed | Scopus (75)

[109]Fede, G., D’Amico, G., Arvaniti, V., Tsochatzis, E., Germani, G., Georgiadis, D. et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012; 56: 810–818
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[110]Wong, F., Nadim, M.K., Kellum, J.A., Salerno, F., Bellomo, R., Gerbes, A. et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011; 60: 702–709
CrossRef | PubMed | Scopus (121)

[111]Francoz, C., Glotz, D., Moreau, R., and Durand, F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010; 52: 605–613
Abstract | Full Text | Full Text PDF | PubMed | Scopus (84)

[112]Eason, J.D., Gonwa, T.A., Davis, C.L., Sung, R.S., Gerber, D., and Bloom, R.D. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008; 8: 2243–2251
CrossRef | PubMed | Scopus (124)

[113]Cruz, R.J. Jr., Dew, M.A., Myaskovsky, L., Goodpaster, B., Fox, K., Fontes, P. et al. Objective radiologic assessment of body composition in patients with end-stage liver disease: going beyond the BMI. Transplantation. 2013; 95: 617–622
CrossRef | PubMed | Scopus (10)

[114]Dick, A.A., Spitzer, A.L., Seifert, C.F., Deckert, A., Carithers, R.L. Jr., Reyes, J.D. et al. Liver transplantation at the extremes of the body mass index. Liver Transpl. 2009; 15: 968–977
CrossRef | PubMed | Scopus (63)

[115]Durand, F., Buyse, S., Francoz, C., Laouenan, C., Bruno, O., Belghiti, J. et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014; 60: 1151–1157
Abstract | Full Text | Full Text PDF | PubMed | Scopus (13)

[116]Langer, G., Grossmann, K., Fleischer, S., Berg, A., Grothues, D., Wienke, A. et al. Nutritional interventions for liver-transplanted patients. Cochrane Database Syst Rev. 2012; 8: CD007605
PubMed

[117]Ferreira, L.G., Anastacio, L.R., and Correia, M.I. The impact of nutrition on cirrhotic patients awaiting liver transplantation. Curr Opin Clin Nutr Metab Care. 2010; 13: 554–561
CrossRef | PubMed | Scopus (12)

[118]Wibaux, C., Legroux-Gerot, I., Dharancy, S., Boleslawski, E., Declerck, N., Canva, V. et al. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine. 2011; 78: 387–391
CrossRef | PubMed | Scopus (0)

[119]Alcalde Vargas, A., Pascasio Acevedo, J.M., Gutierrez Domingo, I., Garcia Jimenez, R., Sousa Martin, J.M., Ferrer Rios, M.T. et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. Transplant Proc. 2012; 44: 1496–1498
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[120]O’Leary, J.G., Demetris, A.J., Friedman, L.S., Gebel, H.M., Halloran, P.F., Kirk, A.D. et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant. 2014; 14: 779–787
CrossRef | PubMed | Scopus (12)

[121]Gustot, T., Durand, F., Lebrec, D., Vincent, J.L., and Moreau, R. Severe sepsis in cirrhosis. Hepatology. 2009; 50: 2022–2033
CrossRef | PubMed | Scopus (141)

[122]Fagiuoli, S., Colli, A., Bruno, R., Craxi, A., Gaeta, G.B., Grossi, P. et al. Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. J Hepatol. 2014; 60: 1075–1089
Abstract | Full Text | Full Text PDF | PubMed | Scopus (3)

[123]Liu, B.M., Chung, K.J., Chen, C.H., Kung, C.T., Ko, S.F., Liu, P.P. et al. Risk factors for the outcome of cirrhotic patients with soft tissue infections. J Clin Gastroenterol. 2008; 42: 312–316
PubMed

[124]Lin, M.N., Tsai, C.C., Hung, T.H., and Tsai, C.C. The risk of cellulitis in cirrhotic patients: a nationwide population-based study in taiwan. Gut Liver. 2012; 6: 482–485
CrossRef | PubMed | Scopus (4)

[125]Cheruvattath, R. and Balan, V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol. 2007; 41: 403–411
CrossRef | PubMed | Scopus (45)

[126]Tandon, P. and Garcia-Tsao, G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008; 28: 26–42
CrossRef | PubMed | Scopus (196)

[127]Caly, W.R. and Strauss, E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993; 18: 353–358
Abstract | Full Text PDF | PubMed | Scopus (307)

[128]Falguera, M., Trujillano, J., Caro, S., Menendez, R., Carratala, J., Ruiz-Gonzalez, A. et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis. 2009; 49: 409–416
CrossRef | PubMed | Scopus (33)

[129]Niederman, M.S., Mandell, L.A., Anzueto, A., Bass, J.B., Broughton, W.A., Campbell, G.D. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163: 1730–1754
CrossRef | PubMed

[130]Lenz, P., Conrad, B., Kucharzik, T., Hilker, E., Fegeler, W., Ullerich, H. et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study. Gastrointest Endosc. 2009; 70: 480–487
Abstract | Full Text | Full Text PDF | PubMed | Scopus (19)

[131]Kulaksiz, H., Rudolph, G., Kloeters-Plachky, P., Sauer, P., Geiss, H., and Stiehl, A. Biliary candida infections in primary sclerosing cholangitis. J Hepatol. 2006; 45: 711–716
Abstract | Full Text | Full Text PDF | PubMed | Scopus (31)

[132]Fischer, S.A. and Avery, R.K. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009; 9: S7–S18
CrossRef | PubMed | Scopus (0)

[133]Samuel, D., Weber, R., Stock, P., Duclos-Vallee, J.C., and Terrault, N. Are HIV-infected patients candidates for liver transplantation?. J Hepatol. 2008; 48: 697–707
Abstract | Full Text | Full Text PDF | PubMed | Scopus (39)

[134]Terrault, N.A., Roland, M.E., Schiano, T., Dove, L., Wong, M.T., Poordad, F. et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012; 18: 716–726
CrossRef | PubMed | Scopus (73)

[135]Francoz, C., Valla, D., and Durand, F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012; 57: 203–212
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[136]Asman, Y., Evenson, A.R., Even-Sapir, E., and Shibolet, O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl. 2015; 21: 572–580
CrossRef | PubMed

[137]Lucey, M.R. and Weinrieb, R.M. Alcohol and substance abuse. Semin Liver Dis. 2009; 29: 66–73
CrossRef | PubMed | Scopus (16)

[138]Jiao, M., Greanya, E.D., Haque, M., Yoshida, E.M., and Soos, J.G. Methadone maintenance therapy in liver transplantation. Prog Transplant. 2010; 20: 209–214 (Quiz 15)
CrossRef | PubMed

[139]Weinrieb, R.M. and Lucey, M.R. Treatment of addictive behaviors in liver transplant patients. Liver Transpl. 2007; 13: S79–S82
CrossRef | PubMed | Scopus (15)

[140]Coffman, K.L. The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. Curr Opin Organ Transplant. 2008; 13: 189–195
CrossRef | PubMed | Scopus (6)

[141]Secunda, K., Gordon, E.J., Sohn, M.W., Shinkunas, L.A., Kaldjian, L.C., Voigt, M.D. et al. National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl. 2013; 19: 395–403
CrossRef | PubMed | Scopus (0)

[142]Nickels, M., Jain, A., Sharma, R., Orloff, M., Tsoulfas, G., Kashyap, R. et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome. Exp Clin Transplant. 2007; 5: 680–685
PubMed

[143]Leithead, J.A., Ferguson, J.W., and Hayes, P.C. Smoking-related morbidity and mortality following liver transplantation. Liver Transpl. 2008; 14: 1159–1164
CrossRef | PubMed | Scopus (33)

[144]Pungpapong, S., Manzarbeitia, C., Ortiz, J., Reich, D.J., Araya, V., Rothstein, K.D. et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl. 2002; 8: 582–587
CrossRef | PubMed | Scopus (75)

[145]van der Heide, F., Dijkstra, G., Porte, R.J., Kleibeuker, J.H., and Haagsma, E.B. Smoking behavior in liver transplant recipients. Liver Transpl. 2009; 15: 648–655
CrossRef | PubMed | Scopus (29)

[146]Roels, L. and Rahmel, A. The European experience. Transpl Int. 2011; 24: 350–367
CrossRef | PubMed | Scopus (35)

[147]Hawton, K., Bergen, H., Simkin, S., Dodd, S., Pocock, P., Bernal, W. et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ. 2013; 346: f403
CrossRef | PubMed | Scopus (26)

[148]<http://www.ont.es/Documents/Datos2014.pdf>.[149]Matesanz, R. Organ procurement in Spain. Lancet. 1992; 340: 733
http://www.ont.es/Documents/Datos2014.pdf | Abstract | PubMed

[150]Matesanz, R., Marazuela, R., Dominguez-Gil, B., Coll, E., Mahillo, B., and de la Rosa, G. The 40 donors per million population plan: an action plan for improvement of organ donation and transplantation in Spain. Transplant Proc. 2009; 41: 3453–3456
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)

[151]Consensus document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol. 2008; 31: 82–91
CrossRef | PubMed | Scopus (0)

[152]Consensus document of the Spanish Society of Liver Transplantation. Waiting lists, liver transplantation and quality indicators. Gastroenterol Hepatol. 2009; 32: 702–716
CrossRef | PubMed | Scopus (0)

[153]III Consensus Meeting of the Spanish Society of Liver Transplantation. Hepatitis C, living-donor liver transplantation, quality of liver grafts and of liver transplantation programs. Cir Esp. 2011; 89: 487–504
CrossRef | PubMed | Scopus (0)

[154]<http://www.organdonation.nhs.uk/statistics/downloads/annual_stats.pdf>.[155]<http://www.odt.nhs.uk/pdf/liver_allocation_policy.pdf>.[156]<http://www.scandiatransplant.org/data/sctp_figures_2013_4Q.pdf>.[157]Fosby, B., Karlsen, T.H., and Melum, E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012; 18: 1–15
http://www.organdonation.nhs.uk/statistics/downloads/annual_stats.pdf | http://www.odt.nhs.uk/pdf/liver_allocation_policy.pdf | http://www.scandiatransplant.org/data/sctp_figures_2013_4Q.pdf | CrossRef | PubMed | Scopus (31)

[158]De Meester, J., Persijn, G.G., Wujciak, T., Opelz, G., and Vanrenterghem, Y. The new Eurotransplant Kidney Allocation System: report one year after implementation. Eurotransplant International Foundation. Transplantation. 1998; 66: 1154–1159
CrossRef | PubMed

[159]Neuberger, J. and Ubel, P.A. Finding a place for public preferences in liver allocation decisions. Transplantation. 2000; 70: 1411–1413
CrossRef | PubMed

[160]Muiesan, P., Girlanda, R., Jassem, W., Melendez, H.V., O’Grady, J., Bowles, M. et al. Single-center experience with liver transplantation from controlled non-heartbeating donors: a viable source of grafts. Ann Surg. 2005; 242: 732–738
CrossRef | PubMed | Scopus (123)

[161]Eurotransplant Manual. 5th Ed. 2010. 18.[162]Kootstra, G., Daemen, J.H., and Oomen, A.P. Categories of non-heart-beating donors. Transplant Proc. 1995; 27: 2893–2894
PubMed

[163]Morrissey, P.E. and Monaco, A.P. Donation after circulatory death: current practices, ongoing challenges, and potential improvements. Transplantation. 2014; 97: 258–264
CrossRef | PubMed | Scopus (25)

[164]Hernandez-Alejandro, R., Caumartin, Y., Chent, C., Levstik, M.A., Quan, D., Muirhead, N. et al. Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre. Can J Surg. 2010; 53: 93–102
PubMed

[165]Schmucker, D.L. and Sanchez, H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res. 2011; 2011: 526379
CrossRef | PubMed | Scopus (24)

[166]Ploeg, R.J., D’Alessandro, A.M., Knechtle, S.J., Stegall, M.D., Pirsch, J.D., Hoffmann, R.M. et al. Risk factors for primary dysfunction after liver transplantation–a multivariate analysis. Transplantation. 1993; 55: 807–813
CrossRef | PubMed

[167]Park, Y., Hirose, R., Coatney, J.L., Ferrell, L., Behrends, M., Roberts, J.P. et al. Ischemia-reperfusion injury is more severe in older versus young rat livers. J Surg Res. 2007; 137: 96–102
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[168]<http://www.eltr.org/Donor-data.html>.[169]Chedid, M.F., Rosen, C.B., Nyberg, S.L., and Heimbach, J.K. Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors. HPB (Oxford). 2014; 16: 852–858
http://www.eltr.org/Donor-data.html | Abstract | Full Text | Full Text PDF | PubMed | Scopus (1)

[170]Uemura, T., Nikkel, L.E., Hollenbeak, C.S., Ramprasad, V., Schaefer, E., and Kadry, Z. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C?. Transpl Int. 2012; 25: 671–679
CrossRef | PubMed | Scopus (0)

[171]Zheng, J., Xiang, J., Zhou, J., Li, Z., Hu, Z., Lo, C.M. et al. Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database. PLoS One. 2014; 9: e98104
CrossRef | PubMed | Scopus (0)

[172]Karayalcin, K., Mirza, D.F., Harrison, R.F., Da Silva, R.F., Hubscher, S.G., Mayer, A.D. et al. The role of dynamic and morphological studies in the assessment of potential liver donors. Transplantation. 1994; 57: 1323–1327
CrossRef | PubMed

[173]D’Alessandro, A.M., Kalayoglu, M., Sollinger, H.W., Hoffmann, R.M., Reed, A., Knechtle, S.J. et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation. 1991; 51: 157–163
CrossRef | PubMed

[174]Deroose, J.P., Kazemier, G., Zondervan, P., Ijzermans, J.N., Metselaar, H.J., and Alwayn, I.P. Hepatic steatosis is not always a contraindication for cadaveric liver transplantation. HPB (Oxford). 2011; 13: 417–425
Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[175]Verran, D., Kusyk, T., Painter, D., Fisher, J., Koorey, D., Strasser, S. et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003; 9: 500–505
CrossRef | PubMed | Scopus (151)

[176]Dutkowski, P., Schlegel, A., Slankamenac, K., Oberkofler, C.E., Adam, R., Burroughs, A.K. et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012; 256: 861–868 (Discussion 8–9)
CrossRef | PubMed

[177]Angelico, M., Nardi, A., Marianelli, T., Caccamo, L., Romagnoli, R., Tisone, G. et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013; 58: 715–723
Abstract | Full Text | Full Text PDF | PubMed | Scopus (17)

[178]Joya-Vazquez, P.P., Dodson, F.S., Dvorchik, I., Gray, E., Chesky, A., Demetris, A.J. et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002; 73: 1598–1602
CrossRef | PubMed

[179]Cholongitas, E., Papatheodoridis, G.V., and Burroughs, A.K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010; 52: 272–279
Abstract | Full Text | Full Text PDF | PubMed | Scopus (91)

[180]Yu, S., Yu, J., Zhang, W., Cheng, L., Ye, Y., Geng, L. et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. J Hepatol. 2014; 61: 809–815
Abstract | Full Text | Full Text PDF | PubMed

[181]Choi, Y., Choi, J.Y., Yi, N.J., Lee, K., Mori, S., Hong, G. et al. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors. Transpl Int. 2013; 26: 1173–1183
CrossRef | PubMed | Scopus (6)

[182]Alvaro, E., Abradelo, M., Fuertes, A., Manrique, A., Colina, F., Alegre, C. et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc. 2012; 44: 1475–1478
Abstract | Full Text | Full Text PDF | PubMed | Scopus (3)

[183]Saab, S., Chang, A.J., Comulada, S., Geevarghese, S.K., Anselmo, R.D., Durazo, F. et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003; 9: 1053–1061
CrossRef | PubMed | Scopus (54)

[184]Northup, P.G., Argo, C.K., Nguyen, D.T., McBride, M.A., Kumer, S.C., Schmitt, T.M. et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010; 23: 1038–1044
CrossRef | PubMed | Scopus (24)

[185]Coilly, A., Furlan, V., Roche, B., Barau, C., Noel, C., Bonhomme-Faivre, L. et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012; 56: 5728–5734
CrossRef | PubMed | Scopus (35)

[186]Coilly, A., Roche, B., Dumortier, J., Leroy, V., Botta-Fridlund, D., Radenne, S. et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60: 78–86
Abstract | Full Text | Full Text PDF | PubMed | Scopus (37)

[187]Miro, J.M., Montejo, M., Castells, L., Rafecas, A., Moreno, S., Aguero, F. et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012; 12: 1866–1876
CrossRef | PubMed | Scopus (50)

[188]Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation-Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep. 2011; 60: 172–174
PubMed

[189]<http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_17.pdf>.[190]Watson, C.J., Roberts, R., Wright, K.A., Greenberg, D.C., Rous, B.A., Brown, C.H. et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant. 2010; 10: 1437–1444
http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_17.pdf | CrossRef | PubMed | Scopus (16)

[191]Feng, S., Buell, J.F., Chari, R.S., DiMaio, J.M., and Hanto, D.W. Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant. 2003; 3: 1481–1487
CrossRef | PubMed | Scopus (47)

[192]Kusne, S. and Smilack, J. Transmission of West Nile virus by organ transplantation. Liver Transpl. 2005; 11: 239–241
CrossRef | PubMed | Scopus (0)

[193]Nett, R.J., Kuehnert, M.J., Ison, M.G., Orlowski, J.P., Fischer, M., and Staples, J.E. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis. 2012; 14: 268–277
CrossRef | PubMed | Scopus (23)

[194]<http://optn.transplant.hrsa.gov/ContentDocuments/Guidance_DTAC_CNS_Infections.pdf>.[195]Morris, M.I., Daly, J.S., Blumberg, E., Kumar, D., Sester, M., Schluger, N. et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012; 12: 2288–2300
http://optn.transplant.hrsa.gov/ContentDocuments/Guidance_DTAC_CNS_Infections.pdf | CrossRef | PubMed | Scopus (26)

[196]Holty, J.E., Gould, M.K., Meinke, L., Keeffe, E.B., and Ruoss, S.J. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009; 15: 894–906
CrossRef | PubMed | Scopus (52)

[197]Ison, M.G. and Grossi, P. Donor-derived infections in solid organ transplantation. Am J Transplant. 2013; 13: 22–30
CrossRef | PubMed | Scopus (16)

[198]Sifri, C.D. and Ison, M.G. Highly resistant bacteria and donor-derived infections: treading in uncharted territory. Transpl Infect Dis. 2012; 14: 223–228
CrossRef | PubMed | Scopus (0)

[199]Theodoropoulos N, Jaramillo A, Penugonda S, Wasik C, Brooks K, Carrera JD, et al. Comparison of syphilis screening tests in deceased organ donors. <https://idsa.confex.com/idsa/2012/webprogram/Handout/id472/POSTER64_521.pdf>. Accessed March, 2013.[200]Cerutti, E., Stratta, C., Romagnoli, R., Serra, R., Lepore, M., Fop, F. et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. Liver Transpl. 2006; 12: 1253–1259
https://idsa.confex.com/idsa/2012/webprogram/Handout/id472/POSTER64_521.pdf | CrossRef | PubMed | Scopus (44)

[201]Gonzalez-Segura, C., Pascual, M., Garcia Huete, L., Canizares, R., Torras, J., Corral, L. et al. Donors with positive blood culture: could they transmit infections to the recipients?. Transplant Proc. 2005; 37: 3664–3666
Abstract | Full Text | Full Text PDF | PubMed | Scopus (21)

[202]Fischer, S.A. and Lu, K. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013; 13: 9–21
CrossRef | PubMed | Scopus (0)

[203]Altclas, J.D., Barcan, L., Nagel, C., Lattes, R., and Riarte, A. Organ transplantation and Chagas disease. JAMA. 2008; 299: 1134 (Author reply-5)
CrossRef | PubMed

[204]Chin-Hong, P.V., Schwartz, B.S., Bern, C., Montgomery, S.P., Kontak, S., Kubak, B. et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant. 2011; 11: 672–680
CrossRef | PubMed | Scopus (44)

[205]Bennett, W.M., Nespral, J.F., Rosson, M.W., and McEvoy, K.M. Use of organs for transplantation from a donor with primary meningoencephalitis due to Naegleria fowleri. Am J Transplant. 2008; 8: 1334–1335
CrossRef | PubMed | Scopus (10)

[206]Singh, N., Huprikar, S., Burdette, S.D., Morris, M.I., Blair, J.E., and Wheat, L.J. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012; 12: 2414–2428
CrossRef | PubMed | Scopus (22)

[207]Feng, S., Goodrich, N.P., Bragg-Gresham, J.L., Dykstra, D.M., Punch, J.D., DebRoy, M.A. et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006; 6: 783–790
CrossRef | PubMed | Scopus (680)

[208]Dutkowski, P., Oberkofler, C.E., Slankamenac, K., Puhan, M.A., Schadde, E., Mullhaupt, B. et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg. 2011; 254: 745–753 (Discussion 53)
CrossRef | PubMed | Scopus (58)

[209]OPTN/SRTR 2011 Annual data report: liver. <http://optn.transplant.hrsa.gov/data/annualreport.asp>.” [Online]. Available: <http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/03_liver_12.pdf>.[210]Tanaka, K., Ogura, Y., Kiuchi, T., Inomata, Y., Uemoto, S., and Furukawa, H. Living donor liver transplantation: Eastern experiences. HPB (Oxford). 2004; 6: 88–94
http://optn.transplant.hrsa.gov/data/annualreport.asp | http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/03_liver_12.pdf | Abstract | Full Text | Full Text PDF | PubMed | Scopus (9)

[211]Gonzalez, F.X., Garcia-Valdecasas, J.C., Grande, L., Pacheco, J.L., Cugat, E., Fuster, J. et al. Vena cava vascular reconstruction during orthotopic liver transplantation: a comparative study. Liver Transpl Surg. 1998; 4: 133–140
CrossRef | PubMed

[212]Parrilla, P., Sanchez-Bueno, F., Figueras, J., Jaurrieta, E., Mir, J., Margarit, C. et al. Analysis of the complications of the piggy-back technique in 1,112 liver transplants. Transplantation. 1999; 67: 1214–1217
CrossRef | PubMed | Scopus (105)

[213]Figueras, J., Llado, L., Ramos, E., Jaurrieta, E., Rafecas, A., Fabregat, J. et al. Temporary portocaval shunt during liver transplantation with vena cava preservation. Results of a prospective randomized study. Liver Transpl. 2001; 7: 904–911
CrossRef | PubMed | Scopus (53)

[214]Yamamoto, S., Wilczek, H.E., Nowak, G., Larsson, M., Oksanen, A., Iwata, T. et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007; 7: 2597–2604
CrossRef | PubMed | Scopus (73)

[215]Pacheco-Moreira, L.F., de Oliveira, M.E., Balbi, E., da Silva, A.C., Miecznikowski, R., de Faria, L.J. et al. A new technical option for domino liver transplantation. Liver Transpl. 2003; 9: 632–633
CrossRef | PubMed | Scopus (19)

[216]Moon, J.I., Kwon, C.H., Joh, J.W., Jung, G.O., Choi, G.S., Park, J.B. et al. Safety of small-for-size grafts in adult-to-adult living donor liver transplantation using the right lobe. Liver Transpl. 2010; 16: 864–869
CrossRef | PubMed | Scopus (31)

[217]Lodge, J.P., Dasgupta, D., Prasad, K.R., Attia, M., Toogood, G.J., Davies, M. et al. Emergency subtotal hepatectomy: a new concept for acetaminophen-induced acute liver failure: temporary hepatic support by auxiliary orthotopic liver transplantation enables long-term success. Ann Surg. 2008; 247: 238–249
CrossRef | PubMed | Scopus (20)

[218]Rela, M., Muiesan, P., Vilca-Melendez, H., Dhawan, A., Baker, A., Mieli-Vergani, G. et al. Auxiliary partial orthotopic liver transplantation for Crigler-Najjar syndrome type I. Ann Surg. 1999; 229: 565–569
CrossRef | PubMed | Scopus (66)

[219]Brandsaeter, B., Hockerstedt, K., Friman, S., Ericzon, B.G., Kirkegaard, P., Isoniemi, H. et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl. 2002; 8: 1055–1062
CrossRef | PubMed | Scopus (74)

[220]Liou, I.W. and Larson, A.M. Role of liver transplantation in acute liver failure. Semin Liver Dis. 2008; 28: 201–209
CrossRef | PubMed | Scopus (41)

[221]van Hoek, B., de Boer, J., Boudjema, K., Williams, R., Corsmit, O., and Terpstra, O.T. Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry. J Hepatol. 1999; 30: 699–705
Abstract | Full Text | Full Text PDF | PubMed | Scopus (105)

[222]Broering, D.C., Schulte am Esch, J., Fischer, L., and Rogiers, X. Split liver transplantation. HPB (Oxford). 2004; 6: 76–82
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[223]Pichlmayr, R., Ringe, B., Gubernatis, G., Hauss, J., and Bunzendahl, H. Transplantation of a donor liver to 2 recipients (splitting transplantation)–a new method in the further development of segmental liver transplantation. Langenbecks Arch Chir. 1988; 373: 127–130
CrossRef | PubMed | Scopus (311)

[224]Rogiers, X., Malago, M., Gawad, K.A., Kuhlencordt, R., Froschle, G., Sturm, E. et al. One year of experience with extended application and modified techniques of split liver transplantation. Transplantation. 1996; 61: 1059–1061
CrossRef | PubMed | Scopus (57)

[225]Lee, W.C., Chan, K.M., Chou, H.S., Wu, T.J., Lee, C.F., Soong, R.S. et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. Ann Surg. 2013; 258: 306–311
CrossRef | PubMed | Scopus (0)

[226]Vagefi, P.A., Parekh, J., Ascher, N.L., Roberts, J.P., and Freise, C.E. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. Arch Surg. 2011; 146: 1052–1059
CrossRef | PubMed | Scopus (25)

[227]Singer, P.A., Siegler, M., Whitington, P.F., Lantos, J.D., Emond, J.C., Thistlethwaite, J.R. et al. Ethics of liver transplantation with living donors. N Engl J Med. 1989; 321: 620–622
CrossRef | PubMed

[228]Yamaoka, Y., Washida, M., Honda, K., Tanaka, K., Mori, K., Shimahara, Y. et al. Liver transplantation using a right lobe graft from a living related donor. Transplantation. 1994; 57: 1127–1130
CrossRef | PubMed

[229]Wilms, C., Walter, J., Kaptein, M., Mueller, L., Lenk, C., Sterneck, M. et al. Long-term outcome of split liver transplantation using right extended grafts in adulthood: a matched pair analysis. Ann Surg. 2006; 244: 865–872 (Discussion 72–73)
CrossRef | PubMed | Scopus (48)

[230]Hwang, S., Lee, S.G., Lee, Y.J., Sung, K.B., Park, K.M., Kim, K.H. et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl. 2006; 12: 920–927
CrossRef | PubMed | Scopus (159)

[231]Dindo, D., Demartines, N., and Clavien, P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205–213
CrossRef | PubMed | Scopus (4575)

[232]Abecassis, M.M., Fisher, R.A., Olthoff, K.M., Freise, C.E., Rodrigo, D.R., Samstein, B. et al. Complications of living donor hepatic lobectomy–a comprehensive report. Am J Transplant. 2012; 12: 1208–1217
CrossRef | PubMed | Scopus (67)

[233]Iwasaki, J., Iida, T., Mizumoto, M., Uemura, T., Yagi, S., Hori, T. et al. Donor morbidity in right and left hemiliver living donor liver transplantation: the impact of graft selection and surgical innovation on donor safety. Transpl Int. 2014; 27: 1205–1213
CrossRef | PubMed

[234]Cheah, Y.L., Simpson, M.A., Pomposelli, J.J., and Pomfret, E.A. Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy: a world-wide survey. Liver Transpl. 2013; 19: 499–506
CrossRef | PubMed | Scopus (36)

[235]Samonakis, D.N., Germani, G., and Burroughs, A.K. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012; 56: 973–983
Abstract | Full Text | Full Text PDF | PubMed | Scopus (29)

[236]Pillai, A.A. and Levitsky, J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009; 15: 4225–4233
CrossRef | PubMed | Scopus (28)

[237]Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I. et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013; 58: 1918–1929
CrossRef | PubMed | Scopus (129)

[238]Mourad, M.M., Liossis, C., Gunson, B.K., Mergental, H., Isaac, J., Muiesan, P. et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 2014; 20: 713–723
CrossRef | PubMed

[239]Rull, R., Garcia Valdecasas, J.C., Grande, L., Fuster, J., Lacy, A.M., Gonzalez, F.X. et al. Intrahepatic biliary lesions after orthotopic liver transplantation. Transpl Int. 2001; 14: 129–134
CrossRef | PubMed

[240]Lee, J.M., Ko, G.Y., Sung, K.B., Gwon, D.I., Yoon, H.K., and Lee, S.G. Long-term efficacy of stent placement for treating inferior vena cava stenosis following liver transplantation. Liver Transpl. 2010; 16: 513–519
PubMed

[241]Guimaraes, M., Uflacker, R., Schonholz, C., Hannegan, C., and Selby, J.B. Stent migration complicating treatment of inferior vena cava stenosis after orthotopic liver transplantation. J Vasc Interv Radiol. 2005; 16: 1247–1252
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[242]Audet, M., Piardi, T., Panaro, F., Cag, M., Habibeh, H., Gheza, F. et al. Four hundred and twenty-three consecutive adults piggy-back liver transplantations with the three suprahepatic veins: was the portal systemic shunt required?. J Gastroenterol Hepatol. 2010; 25: 591–596
CrossRef | PubMed | Scopus (12)

[243]Bhangui, P., Lim, C., Salloum, C., Andreani, P., Sebbagh, M., Hoti, E. et al. Caval inflow to the graft for liver transplantation in patients with diffuse portal vein thrombosis: a 12-year experience. Ann Surg. 2011; 254: 1008–1016
CrossRef | PubMed | Scopus (17)

[244]Londono, M.C., Balderramo, D., and Cardenas, A. Management of biliary complications after orthotopic liver transplantation: the role of endoscopy. World J Gastroenterol. 2008; 14: 493–497
CrossRef | PubMed | Scopus (34)

[245]Sanchez Cabus, S., Calatayud, D., Garcia-Roca, R., Ferrer, J., Marti, J., Navasa, M. et al. The biliary complications in live donor liver transplant do not affect the long-term results. Cir Esp. 2013; 91: 17–24
CrossRef | PubMed

[246]Selck, F.W., Grossman, E.B., Ratner, L.E., and Renz, J.F. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008; 248: 599–607
PubMed

[247]Graziadei, I.W., Wiesner, R.H., Batts, K.P., Marotta, P.J., LaRusso, N.F., Porayko, M.K. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999; 29: 1050–1056
CrossRef | PubMed

[248]Nishida, S., Nakamura, N., Kadono, J., Komokata, T., Sakata, R., Madariaga, J.R. et al. Intrahepatic biliary strictures after liver transplantation. J Hepatobiliary Pancreat Surg. 2006; 13: 511–516
CrossRef | PubMed | Scopus (46)

[249]Sharma, S., Gurakar, A., and Jabbour, N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl. 2008; 14: 759–769
CrossRef | PubMed | Scopus (121)

[250]Verdonk, R.C., Buis, C.I., Porte, R.J., van der Jagt, E.J., Limburg, A.J., van den Berg, A.P. et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. Liver Transpl. 2006; 12: 726–735
CrossRef | PubMed | Scopus (120)

[251]Linhares, M.M., Gonzalez, A.M., Goldman, S.M., Coelho, R.D., Sato, N.Y., Moura, R.M. et al. Magnetic resonance cholangiography in the diagnosis of biliary complications after orthotopic liver transplantation. Transplant Proc. 2004; 36: 947–948
Abstract | Full Text | Full Text PDF | PubMed | Scopus (26)

[252]Sung, R.S., Campbell, D.A. Jr., Rudich, S.M., Punch, J.D., Shieck, V.L., Armstrong, J.M. et al. Long-term follow-up of percutaneous transhepatic balloon cholangioplasty in the management of biliary strictures after liver transplantation. Transplantation. 2004; 77: 110–115
CrossRef | PubMed | Scopus (46)

[253]Shah, S.A., Grant, D.R., McGilvray, I.D., Greig, P.D., Selzner, M., Lilly, L.B. et al. Biliary strictures in 130 consecutive right lobe living donor liver transplant recipients: results of a Western center. Am J Transplant. 2007; 7: 161–167
CrossRef | PubMed | Scopus (97)

[254]Hwang, S., Lee, S.G., Sung, K.B., Park, K.M., Kim, K.H., Ahn, C.S. et al. Long-term incidence, risk factors, and management of biliary complications after adult living donor liver transplantation. Liver Transpl. 2006; 12: 831–838
CrossRef | PubMed | Scopus (94)

[255]Tashiro, H., Itamoto, T., Sasaki, T., Ohdan, H., Fudaba, Y., Amano, H. et al. Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg. 2007; 31: 2222–2229
CrossRef | PubMed | Scopus (40)

[256]Yoo, P.S., Umman, V., Rodriguez-Davalos, M.I., and Emre, S.H. Retransplantation of the liver: review of current literature for decision making and technical considerations. Transplant Proc. 2013; 45: 854–859
Abstract | Full Text | Full Text PDF | PubMed | Scopus (10)

[257]Pfitzmann, R., Benscheidt, B., Langrehr, J.M., Schumacher, G., Neuhaus, R., and Neuhaus, P. Trends and experiences in liver retransplantation over 15 years. Liver Transpl. 2007; 13: 248–257
CrossRef | PubMed | Scopus (61)

[258]Chen, G.H., Fu, B.S., Cai, C.J., Lu, M.Q., Yang, Y., Yi, S.H. et al. A single-center experience of retransplantation for liver transplant recipients with a failing graft. Transplant Proc. 2008; 40: 1485–1487
Abstract | Full Text | Full Text PDF | PubMed | Scopus (0)

[259]Watt, K.D., Lyden, E.R., and McCashland, T.M. Poor survival after liver retransplantation: is hepatitis C to blame?. Liver Transpl. 2003; 9: 1019–1024
CrossRef | PubMed | Scopus (72)

[260]Ghabril, M., Dickson, R., and Wiesner, R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant. 2008; 8: 404–411
CrossRef | PubMed | Scopus (42)

[261]Rosen, H.R., Madden, J.P., and Martin, P. A model to predict survival following liver retransplantation. Hepatology. 1999; 29: 365–370
CrossRef | PubMed | Scopus (117)

[262]Yao, F.Y., Saab, S., Bass, N.M., Hirose, R., Ly, D., Terrault, N. et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology. 2004; 39: 230–238
CrossRef | PubMed | Scopus (71)

[263]Wiesner, R.H. and Fung, J.J. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011; 17: S1–S9
CrossRef | PubMed | Scopus (26)

[264]McAlister, V.C., Haddad, E., Renouf, E., Malthaner, R.A., Kjaer, M.S., and Gluud, L.L. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006; 6: 1578–1585
CrossRef | PubMed | Scopus (109)

[265]O’Grady, J.G., Hardy, P., Burroughs, A.K., and Elbourne, D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant. 2007; 7: 137–141
CrossRef | PubMed | Scopus (38)

[266]Dumortier, J., Guillaud, O., and Boillot, O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl. 2013; 19: 529–533
CrossRef | PubMed | Scopus (0)

[267]Trunecka, P., Boillot, O., Seehofer, D., Pinna, A.D., Fischer, L., Ericzon, B.G. et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010; 10: 2313–2323
CrossRef | PubMed | Scopus (52)

[268]Beckebaum, S., Iacob, S., Sweid, D., Sotiropoulos, G.C., Saner, F., Kaiser, G. et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int. 2011; 24: 666–675
CrossRef | PubMed | Scopus (28)

[269]Nielsen, O.H., Vainer, B., and Rask-Madsen, J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001; 15: 1699–1708
CrossRef | PubMed | Scopus (126)

[270]Wiesner, R., Rabkin, J., Klintmalm, G., McDiarmid, S., Langnas, A., Punch, J. et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001; 7: 442–450
CrossRef | PubMed | Scopus (185)

[271]Sterneck, M., Fischer, L., Gahlemann, C., Gundlach, M., Rogiers, X., and Broelsch, C. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann Transplant. 2000; 5: 43–46
PubMed

[272]Fischer, L., Sterneck, M., Gahlemann, C.G., Malago, M., Rogiers, X., and Broelsch, C.E. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc. 2000; 32: 2125–2127
Abstract | Full Text | Full Text PDF | PubMed | Scopus (14)

[273]Budde, K., Curtis, J., Knoll, G., Chan, L., Neumayer, H.H., Seifu, Y. et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004; 4: 237–243
CrossRef | PubMed | Scopus (184)

[274]Ciancio, G., Burke, G.W., Gaynor, J.J., Roth, D., Sageshima, J., Kupin, W. et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation. 2008; 86: 67–74
CrossRef | PubMed | Scopus (41)

[275]Salvadori, M., Holzer, H., de Mattos, A., Sollinger, H., Arns, W., Oppenheimer, F. et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004; 4: 231–236
CrossRef | PubMed | Scopus (212)

[276]Johnston, A., He, X., and Holt, D.W. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation. 2006; 82: 1413–1418
CrossRef | PubMed | Scopus (36)

[277]Cantisani, G.P., Zanotelli, M.L., Gleisner, A.L., de Mello Brandao, A., and Marroni, C.A. Enteric-coated mycophenolate sodium experience in liver transplant patients. Transplant Proc. 2006; 38: 932–933
Abstract | Full Text | Full Text PDF | PubMed | Scopus (8)

[278]Miras, M., Carballo, F., Egea, J., Martinez, C., Alvarez-Lopez, M.R., Sanchez-Bueno, F. et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc. 2007; 39: 2314–2317
Abstract | Full Text | Full Text PDF | PubMed | Scopus (11)

[279]Dunkelberg, J.C., Trotter, J.F., Wachs, M., Bak, T., Kugelmas, M., Steinberg, T. et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003; 9: 463–468
CrossRef | PubMed | Scopus (91)

[280]McAlister, V.C., Peltekian, K.M., Malatjalian, D.A., Colohan, S., MacDonald, S., Bitter-Suermann, H. et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. 2001; 7: 701–708
CrossRef | PubMed | Scopus (125)

[281]McKenna, G.J. and Trotter, J.F. Sirolimus–it doesn’t deserve its bad Rap(a). J Hepatol. 2012; 56: 285–287
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5)

[282]Murgia, M.G., Jordan, S., and Kahan, B.D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 1996; 49: 209–216
CrossRef | PubMed

[283]Neuhaus, P., Clavien, P.A., Kittur, D., Salizzoni, M., Rimola, A., Abeywickrama, K. et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002; 8: 132–142
CrossRef | PubMed | Scopus (140)

[284]Goralczyk, A.D., Hauke, N., Bari, N., Tsui, T.Y., Lorf, T., and Obed, A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology. 2011; 54: 541–554
CrossRef | PubMed | Scopus (0)

[285]Calmus, Y., Scheele, J.R., Gonzalez-Pinto, I., Jaurrieta, E.J., Klar, E., Pageaux, G.P. et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002; 8: 123–131
CrossRef | PubMed | Scopus (77)

[286]Hirose, R., Roberts, J.P., Quan, D., Osorio, R.W., Freise, C., Ascher, N.L. et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation. 2000; 69: 307–311
CrossRef | PubMed

[287]Bajjoka, I., Hsaiky, L., Brown, K., and Abouljoud, M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 2008; 14: 66–72
CrossRef | PubMed | Scopus (24)

[288]Soliman, T., Hetz, H., Burghuber, C., Gyori, G., Silberhumer, G., Steininger, R. et al. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 2007; 20: 447–452
CrossRef | PubMed | Scopus (12)

[289]Klintmalm, G.B. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2011; 11: 1765–1766
CrossRef | PubMed | Scopus (23)

[290]Trofe-Clark, J., Gabardi, S., McDevitt-Potter, L., and Alloway, R.R. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2012; 12: 792–793 (Author reply 4)
CrossRef | PubMed | Scopus (9)

[291]Latran and Latran, M. Response to Klintmalm on the use of generic immunosuppression. Am J Transplant. 2012; 12: 791 (Author reply 4)
CrossRef | PubMed | Scopus (0)

[292]Alloway, R.R., Isaacs, R., Lake, K., Hoyer, P., First, R., Helderman, H. et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant. 2003; 3: 1211–1215
CrossRef | PubMed | Scopus (66)

[293]Taube, D., Jones, G., O’Beirne, J., Wennberg, L., Connor, A., Rasmussen, A. et al. Generic tacrolimus in solid organ transplantation. Clin Transplant. 2014; 28: 623–632
CrossRef | PubMed | Scopus (0)

[294]Ensor, C.R., Trofe-Clark, J., Gabardi, S., McDevitt-Potter, L.M., and Shullo, M.A. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy. 2011; 31: 1111–1129
CrossRef | PubMed | Scopus (26)

[295]Ojo, A.O., Held, P.J., Port, F.K., Wolfe, R.A., Leichtman, A.B., Young, E.W. et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349: 931–940
CrossRef | PubMed | Scopus (1075)

[296]de Mattos, A.M., Olyaei, A.J., and Bennett, W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000; 35: 333–346
Abstract | Full Text | Full Text PDF | PubMed

[297]Calmus, Y., Kamar, N., Gugenheim, J., Duvoux, C., Ducerf, C., Wolf, P. et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation. 2010; 89: 1504–1510
CrossRef | PubMed | Scopus (13)

[298]Neuberger, J.M., Mamelok, R.D., Neuhaus, P., Pirenne, J., Samuel, D., Isoniemi, H. et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant. 2009; 9: 327–336
CrossRef | PubMed | Scopus (98)

[299]Yoshida, E.M., Marotta, P.J., Greig, P.D., Kneteman, N.M., Marleau, D., Cantarovich, M. et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005; 11: 1064–1072
CrossRef | PubMed | Scopus (72)

[300]Biselli, M., Vitale, G., Gramenzi, A., Riili, A., Berardi, S., Camma, C. et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant. 2009; 23: 191–198
CrossRef | PubMed | Scopus (13)

[301]Cicinnati, V.R., Yu, Z., Klein, C.G., Sotiropoulos, G.C., Saner, F., Malago, M. et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients–assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther. 2007; 26: 1195–1208
CrossRef | PubMed | Scopus (30)

[302]Creput, C., Blandin, F., Deroure, B., Roche, B., Saliba, F., Charpentier, B. et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl. 2007; 13: 1004–1010
CrossRef | PubMed | Scopus (29)

[303]Koch, R.O., Graziadei, I.W., Schulz, F., Nachbaur, K., Konigsrainer, A., Margreiter, R. et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int. 2004; 17: 518–524
CrossRef | PubMed | Scopus (44)

[304]Pageaux, G.P., Rostaing, L., Calmus, Y., Duvoux, C., Vanlemmens, C., Hardgwissen, J. et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 2006; 12: 1755–1760
CrossRef | PubMed | Scopus (69)

[305]Reich, D.J., Clavien, P.A., and Hodge, E.E. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005; 80: 18–25
CrossRef | PubMed | Scopus (54)

[306]Dharancy, S., Iannelli, A., Hulin, A., Declerck, N., Schneck, A.S., Mathurin, P. et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant. 2009; 9: 610–613
CrossRef | PubMed | Scopus (15)

[307]Moreno Planas, J.M., Cuervas-Mons Martinez, V., Rubio Gonzalez, E., Gomez Cruz, A., Lopez-Monclus, J., Sanchez-Turrion, V. et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant. 2004; 4: 1650–1655
CrossRef | PubMed | Scopus (48)

[308]Raimondo, M.L., Dagher, L., Papatheodoridis, G.V., Rolando, N., Patch, D.W., Davidson, B.R. et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation. 2003; 75: 186–190
CrossRef | PubMed | Scopus (65)

[309]Robson, R., Cecka, J.M., Opelz, G., Budde, M., and Sacks, S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005; 5: 2954–2960
CrossRef | PubMed | Scopus (106)

[310]Schlitt, H.J., Barkmann, A., Boker, K.H., Schmidt, H.H., Emmanouilidis, N., Rosenau, J. et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001; 357: 587–591
Abstract | Full Text | Full Text PDF | PubMed | Scopus (193)

[311]Duvoux, C. and Pageaux, G.P. Immunosuppression in liver transplant recipients with renal impairment. J Hepatol. 2011; 54: 1041–1054
Abstract | Full Text | Full Text PDF | PubMed | Scopus (10)

[312]Chang, B.S., Hong, W.S., Lee, E., Yeo, S.M., Bang, I.S., Chung, Y.H. et al. Ultramicroscopic observations on morphological changes in hair during 25 years of weathering. Forensic Sci Int. 2005; 151: 193–200
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[313]Hong, M., Angus, P.W., Jones, R.M., Vaughan, R.B., and Gow, P.J. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant. 2005; 19: 193–198
CrossRef | PubMed | Scopus (12)

[314]Sandborn, W.J., Hay, J.E., Porayko, M.K., Gores, G.J., Steers, J.L., Krom, R.A. et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994; 19: 925–932
CrossRef | PubMed

[315]Germani, G., Pleguezuelo, M., Villamil, F., Vaghjiani, S., Tsochatzis, E., Andreana, L. et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 2009; 9: 1725–1731
CrossRef | PubMed | Scopus (48)

[316]Asrani, S.K., Leise, M.D., West, C.P., Murad, M.H., Pedersen, R.A., Erwin, P.J. et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology. 2010; 52: 1360–1370
CrossRef | PubMed | Scopus (33)

[317]Abdelmalek, M.F., Humar, A., Stickel, F., Andreone, P., Pascher, A., Barroso, E. et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012; 12: 694–705
CrossRef | PubMed | Scopus (29)

[318]Teperman, L., Moonka, D., Sebastian, A., Sher, L., Marotta, P., Marsh, C. et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013; 19: 675–689
CrossRef | PubMed | Scopus (15)

[319]Castroagudin, J.F., Molina, E., Romero, R., Otero, E., Tome, S., and Varo, E. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009; 15: 1792–1797
CrossRef | PubMed | Scopus (29)

[320]De Simone, P., Metselaar, H.J., Fischer, L., Dumortier, J., Boudjema, K., Hardwigsen, J. et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009; 15: 1262–1269
CrossRef | PubMed | Scopus (52)

[321]Fischer, L., Klempnauer, J., Beckebaum, S., Metselaar, H.J., Neuhaus, P., Schemmer, P. et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation–PROTECT. Am J Transplant. 2012; 12: 1855–1865
CrossRef | PubMed | Scopus (41)

[322]Sterneck, M., Kaiser, G.M., Heyne, N., Richter, N., Rauchfuss, F., Pascher, A. et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014; 14: 701–710
CrossRef | PubMed | Scopus (12)

[323]De Simone, P., Nevens, F., De Carlis, L., Metselaar, H.J., Beckebaum, S., Saliba, F. et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012; 12: 3008–3020
CrossRef | PubMed | Scopus (61)

[324]Saliba, F., De Simone, P., Nevens, F., De Carlis, L., Metselaar, H.J., Beckebaum, S. et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013; 13: 1734–1745
CrossRef | PubMed | Scopus (24)

[325]Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., and Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003; 38: 1282–1288
CrossRef | PubMed | Scopus (383)

[326]Berenguer, M., Royuela, A., and Zamora, J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007; 13: 21–29
CrossRef | PubMed | Scopus (129)

[327]Firpi, R.J., Soldevila-Pico, C., Morelli, G.G., Cabrera, R., Levy, C., Clark, V.C. et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci. 2010; 55: 196–203
CrossRef | PubMed | Scopus (41)

[328]Berenguer, M., Lopez-Labrador, F.X., Greenberg, H.B., and Wright, T.L. Hepatitis C virus and the host: an imbalance induced by immunosuppression?. Hepatology. 2000; 32: 433–435
CrossRef | PubMed

[329]Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004; 41: 830–836
Abstract | Full Text | Full Text PDF | PubMed | Scopus (240)

[330]Berenguer, M., Aguilera, V., Prieto, M., San Juan, F., Rayon, J.M., Benlloch, S. et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006; 44: 717–722
Abstract | Full Text | Full Text PDF | PubMed | Scopus (136)

[331]Samonakis, D.N., Triantos, C.K., Thalheimer, U., Quaglia, A., Leandro, G., Teixeira, R. et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005; 11: 386–395
CrossRef | PubMed | Scopus (86)

[332]Vivarelli, M., Burra, P., La Barba, G., Canova, D., Senzolo, M., Cucchetti, A. et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol. 2007; 47: 793–798
Abstract | Full Text | Full Text PDF | PubMed | Scopus (79)

[333]Manousou, P., Cholongitas, E., Samonakis, D., Tsochatzis, E., Corbani, A., Dhillon, A.P. et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014; 63: 1005–1013
CrossRef | PubMed | Scopus (0)

[334]Filipponi, F., Callea, F., Salizzoni, M., Grazi, G.L., Fassati, L.R., Rossi, M. et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation. 2004; 78: 1488–1495
CrossRef | PubMed | Scopus (68)

[335]Kato, T., Gaynor, J.J., Yoshida, H., Montalvano, M., Takahashi, H., Pyrsopoulos, N. et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation. 2007; 84: 829–835
CrossRef | PubMed | Scopus (52)

[336]Klintmalm, G.B., Davis, G.L., Teperman, L., Netto, G.J., Washburn, K., Rudich, S.M. et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011; 17: 1394–1403
CrossRef | PubMed | Scopus (53)

[337]Segev, D.L., Sozio, S.M., Shin, E.J., Nazarian, S.M., Nathan, H., Thuluvath, P.J. et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl. 2008; 14: 512–525
CrossRef | PubMed | Scopus (90)

[338]Kornberg, A., Kupper, B., Tannapfel, A., Hommann, M., and Scheele, J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol. 2005; 5: 107–115
CrossRef | PubMed | Scopus (31)

[339]Patsenker, E., Schneider, V., Ledermann, M., Saegesser, H., Dorn, C., Hellerbrand, C. et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011; 55: 388–398
Abstract | Full Text | Full Text PDF | PubMed | Scopus (49)

[340]Mannova, P. and Beretta, L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol. 2005; 79: 8742–8749
CrossRef | PubMed | Scopus (95)

[341]McKenna, G.J., Trotter, J.F., Klintmalm, E., Onaca, N., Ruiz, R., Jennings, L.W. et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant. 2011; 11: 2379–2387
CrossRef | PubMed | Scopus (51)

[342]De Simone, P., Carrai, P., Precisi, A., Petruccelli, S., Baldoni, L., Balzano, E. et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int. 2009; 22: 279–286
CrossRef | PubMed | Scopus (39)

[343]De Ruvo, N., Cucchetti, A., Lauro, A., Masetti, M., Cautero, N., Di Benedetto, F. et al. Preliminary results of a “prope” tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation. 2005; 80: 8–12
CrossRef | PubMed | Scopus (33)

[344]Garcia-Saenz-de-Sicilia, M., Olivera-Martinez, M.A., Grant, W.J., Mercer, D.F., Baojjang, C., Langnas, A. et al. Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation. Dig Dis Sci. 2014; 59: 2804–2812
CrossRef | PubMed | Scopus (0)

[345]Marcos, A., Eghtesad, B., Fung, J.J., Fontes, P., Patel, K., Devera, M. et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004; 78: 966–971
CrossRef | PubMed | Scopus (120)

[346]Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M. et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999; 397: 530–534
CrossRef | PubMed | Scopus (730)

[347]Freise, C.E., Ferrell, L., Liu, T., Ascher, N.L., and Roberts, J.P. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation. 1999; 67: 510–513
CrossRef | PubMed

[348]Rodriguez-Peralvarez, M., Tsochatzis, E., Naveas, M.C., Pieri, G., Garcia-Caparros, C., O’Beirne, J. et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013; 59: 1193–1199
Abstract | Full Text | Full Text PDF | PubMed | Scopus (15)

[349]Vivarelli, M., Bellusci, R., Cucchetti, A., Cavrini, G., De Ruvo, N., Aden, A.A. et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation. 2002; 74: 1746–1751
CrossRef | PubMed

[350]Decaens, T., Roudot-Thoraval, F., Bresson-Hadni, S., Meyer, C., Gugenheim, J., Durand, F. et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol. 2006; 12: 7319–7325
PubMed

[351]Vivarelli, M., Cucchetti, A., La Barba, G., Ravaioli, M., Del Gaudio, M., Lauro, A. et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008; 248: 857–862
CrossRef | PubMed | Scopus (70)

[352]Liang, W., Wang, D., Ling, X., Kao, A.A., Kong, Y., Shang, Y. et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012; 18: 62–69
CrossRef | PubMed | Scopus (54)

[353]Menon, K.V., Hakeem, A.R., and Heaton, N.D. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2013; 37: 411–419
CrossRef | PubMed | Scopus (34)

[354]Schnitzbauer, A.A., Zuelke, C., Graeb, C., Rochon, J., Bilbao, I., Burra, P. et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010; 10: 190
CrossRef | PubMed | Scopus (84)

[355]Geissler, E.K., Schnitzbauer, A.A., Zülke, C., Lamby, P.E., Proneth, A., Duvoux, C. et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma. Transplantation. 2015; (in press)

[356]Shiah, H.S., Chen, C.Y., Dai, C.Y., Hsiao, C.F., Lin, Y.J., Su, W.C. et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013; 37: 62–73
CrossRef | PubMed | Scopus (21)

[357]Zhu, A.X., Abrams, T.A., Miksad, R., Blaszkowsky, L.S., Meyerhardt, J.A., Zheng, H. et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011; 117: 5094–5102
CrossRef | PubMed | Scopus (85)

[358]Tjon, A.S., Sint Nicolaas, J., Kwekkeboom, J., de Man, R.A., Kazemier, G., Tilanus, H.W. et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl. 2010; 16: 837–846
CrossRef | PubMed | Scopus (28)

[359]Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B. et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351: 623–628
Abstract | Full Text | Full Text PDF | PubMed | Scopus (429)

[360]O’Neill, J.O., Edwards, L.B., and Taylor, D.O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25: 1186–1191
Abstract | Full Text | Full Text PDF | PubMed | Scopus (67)

[361]Lebbe, C., Euvrard, S., Barrou, B., Pouteil-Noble, C., Garnier, J.L., Glotz, D. et al. Sirolimus conversion for patients with posttransplant Kaposi’s sarcoma. Am J Transplant. 2006; 6: 2164–2168
CrossRef | PubMed | Scopus (77)

[362]Calne, R., Friend, P., Moffatt, S., Bradley, A., Hale, G., Firth, J. et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998; 351: 1701–1702
Abstract | Full Text | Full Text PDF | PubMed

[363]Starzl, T.E. Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res. 2007; 38: 6–41
CrossRef | PubMed | Scopus (21)

[364]Starzl, T.E. Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med. 2008; 358: 407–411
CrossRef | PubMed | Scopus (44)

[365]Assy, N., Adams, P.C., Myers, P., Simon, V., Minuk, G.Y., Wall, W. et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation. 2007; 83: 1571–1576
CrossRef | PubMed | Scopus (31)

[366]Devlin, J., Doherty, D., Thomson, L., Wong, T., Donaldson, P., Portmann, B. et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology. 1998; 27: 926–933
CrossRef | PubMed | Scopus (160)

[367]Eason, J.D., Cohen, A.J., Nair, S., Alcantera, T., and Loss, G.E. Tolerance: is it worth the risk?. Transplantation. 2005; 79: 1157–1159
CrossRef | PubMed | Scopus (58)

[368]Feng, S., Ekong, U.D., Lobritto, S.J., Demetris, A.J., Roberts, J.P., Rosenthal, P. et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012; 307: 283–293
CrossRef | PubMed | Scopus (91)

[369]Girlanda, R., Rela, M., Williams, R., O’Grady, J.G., and Heaton, N.D. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc. 2005; 37: 1708–1709
Abstract | Full Text | Full Text PDF | PubMed | Scopus (52)

[370]Mazariegos, G.V., Reyes, J., Marino, I.R., Demetris, A.J., Flynn, B., Irish, W. et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997; 63: 243–249
CrossRef | PubMed | Scopus (269)

[371]Oike, F., Yokoi, A., Nishimura, E., Ogura, Y., Fujimoto, Y., Kasahara, M. et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc. 2002; 34: 1521
Abstract | Full Text | Full Text PDF | PubMed | Scopus (23)

[372]Pons, J.A., Yelamos, J., Ramirez, P., Oliver-Bonet, M., Sanchez, A., Rodriguez-Gago, M. et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003; 75: 1045–1047
CrossRef | PubMed

[373]Takatsuki, M., Uemoto, S., Inomata, Y., Egawa, H., Kiuchi, T., Fujita, S. et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001; 72: 449–454
CrossRef | PubMed

[374]Tisone, G., Orlando, G., Cardillo, A., Palmieri, G., Manzia, T.M., Baiocchi, L. et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006; 44: 702–709
Abstract | Full Text | Full Text PDF | PubMed | Scopus (90)

[375]Tryphonopoulos, P., Tzakis, A.G., Weppler, D., Garcia-Morales, R., Kato, T., Madariaga, J.R. et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant. 2005; 5: 608–613
CrossRef | PubMed | Scopus (60)

[376]Orlando, G., Manzia, T., Baiocchi, L., Sanchez-Fueyo, A., Angelico, M., and Tisone, G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol. 2008; 20: 43–47
CrossRef | PubMed | Scopus (42)

[377]Pons, J.A., Ramirez, P., Revilla-Nuin, B., Pascual, D., Baroja-Mazo, A., Robles, R. et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant. 2009; 23: 329–336
CrossRef | PubMed | Scopus (25)

[378]Londono, M.C., Rimola, A., O’Grady, J., and Sanchez-Fueyo, A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol. 2013; 59: 872–879
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5)

[379]Benitez, C., Londono, M.C., Miquel, R., Manzia, T.M., Abraldes, J.G., Lozano, J.J. et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013; 58: 1824–1835
CrossRef | PubMed | Scopus (21)

[380]Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M. et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680–687
CrossRef | PubMed | Scopus (333)

[381]Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., and Lucey, M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122: 889–896
Abstract | Full Text | Full Text PDF | PubMed

[382]Berenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32: 673–684
Abstract | Full Text | Full Text PDF | PubMed | Scopus (585)

[383]Blasco, A., Forns, X., Carrion, J.A., Garcia-Pagan, J.C., Gilabert, R., Rimola, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006; 43: 492–499
CrossRef | PubMed | Scopus (174)

[384]Carrion, J.A., Torres, F., Crespo, G., Miquel, R., Garcia-Valdecasas, J.C., Navasa, M. et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology. 2010; 51: 23–34
CrossRef | PubMed | Scopus (77)

[385]Crespo, G., Lens, S., Gambato, M., Carrion, J.A., Marino, Z., Londono, M.C. et al. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. Am J Transplant. 2014; 14: 375–383
CrossRef | PubMed | Scopus (2)

[386]Terrault, N.A. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: S58–S66
CrossRef | PubMed | Scopus (24)

[387]Brown, K.A., Fontana, R.J., Russo, M.W., Levitsky, J., Yoshida, E.M., Vargas, H.E. et al. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter REFRESH study. Hepatology. 2013; 58: 209A

[388]Coilly, A., Dumortier, J., Botta-Fridlund, D., Latournerie, M., Leroy, V., Pageaux, G.P. et al. Sustained virological response after protease inhibitorbased therapy for hepatitis C recurrence after liver transplantation: a multicentric european experience. Hepatology. 2013; 58: 316A

[389]Faisal, N., Renner, E.L., Bilodeau, M., Yoshida, E.M., Wong, P., Ma, M.M. et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicentre experience. Hepatology. 2013; 58: 238A

[390]Gambato, M., Lens, S., Navasa, M., and Forns, X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014; 61: S120–S131
Abstract | Full Text | Full Text PDF | PubMed | Scopus (6)

[391]Coilly, A., Roche, B., Duclos-Vallee, J.C., and Samuel, D. Management of HCV transplant patients with triple therapy. Liver Int. 2014; 34: 46–52
CrossRef | PubMed | Scopus (13)

[392]Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr., Curry, M.P., Kwo, P.Y. et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148: 108–117
Abstract | Full Text | Full Text PDF | PubMed | Scopus (42)

[393]Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D. et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015; 61: 1485–1494
CrossRef | PubMed | Scopus (14)

[394]Kwo, P.Y., Mantry, P.S., Coakley, E., Te, H.S., Vargas, H.E., Brown, R.S. Jr. et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014; 371: 2375–2382
CrossRef | PubMed | Scopus (39)

[395]Reddy, R.K., Everson, G.T., Flamm, S.L., Denning, J.M., Arterburn, S., Brandt-Sarif, T. et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence. preliminary results of a prospective, multicenter study. Hepatology. 2014; 60: 200A

[396]Dieterich, D., Bacon, B.R., Flamm, S.L., Kowdley, K.V., Milligan, S., Tsai, N. et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014; 60: 220A

[397]Brown, R.S., Reddy, K.R.J., O’Leary, J.G., Kuo, A., Morelli, G., Stravitz, R.T. et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology. 2014; 60: 1269A

[398]Berenguer, M., Palau, A., Aguilera, V., Rayon, J.M., Juan, F.S., and Prieto, M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008; 8: 679–687
CrossRef | PubMed | Scopus (156)

[399]Carrion, J.A., Navasa, M., Garcia-Retortillo, M., Garcia-Pagan, J.C., Crespo, G., Bruguera, M. et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746–1756
Abstract | Full Text | Full Text PDF | PubMed | Scopus (239)

[400]Samuel, D., Muller, R., Alexander, G., Fassati, L., Ducot, B., Benhamou, J.P. et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329: 1842–1847
CrossRef | PubMed | Scopus (730)

[401]Samuel, D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol. 2001; 34: 943–945
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[402]Cholongitas, E., Goulis, J., Akriviadis, E., and Papatheodoridis, G.V. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011; 17: 1176–1190
CrossRef | PubMed | Scopus (49)

[403]Dumortier, J., Chevallier, P., Scoazec, J.Y., Berger, F., and Boillot, O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003; 3: 999–1002
CrossRef | PubMed | Scopus (55)

[404]Markowitz, J.S., Martin, P., Conrad, A.J., Markmann, J.F., Seu, P., Yersiz, H. et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998; 28: 585–589
CrossRef | PubMed | Scopus (423)

[405]Loomba, R., Rowley, A.K., Wesley, R., Smith, K.G., Liang, T.J., Pucino, F. et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008; 6: 696–700
Abstract | Full Text | Full Text PDF | PubMed | Scopus (54)

[406]Gane, E.J., Angus, P.W., Strasser, S., Crawford, D.H., Ring, J., Jeffrey, G.P. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007; 132: 931–937
Abstract | Full Text | Full Text PDF | PubMed | Scopus (186)

[407]Buti, M., Mas, A., Prieto, M., Casafont, F., Gonzalez, A., Miras, M. et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003; 38: 811–817
Abstract | Full Text | Full Text PDF | PubMed | Scopus (145)

[408]Fung, J., Chan, S.C., Cheung, C., Yuen, M.F., Chok, K.S., Sharr, W. et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013; 108: 942–948
CrossRef | PubMed | Scopus (30)

[409]Terrault, N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?. Am J Gastroenterol. 2013; 108: 949–951
CrossRef | PubMed

[410]Lucey, M.R., Schaubel, D.E., Guidinger, M.K., Tome, S., and Merion, R.M. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology. 2009; 50: 400–406
CrossRef | PubMed | Scopus (38)

[411]Faure, S., Herrero, A., Jung, B., Duny, Y., Daures, J.P., Mura, T. et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol. 2012; 57: 306–312
Abstract | Full Text | Full Text PDF | PubMed | Scopus (27)

[412]Vaillant, G.E. A 60-year follow-up of alcoholic men. Addiction. 2003; 98: 1043–1051
CrossRef | PubMed | Scopus (144)

[413]DiMartini, A., Crone, C., and Dew, M.A. Alcohol and substance use in liver transplant patients. Clin Liver Dis. 2011; 15: 727–751
Abstract | Full Text | Full Text PDF | PubMed | Scopus (11)

[414]DiMartini, A., Dew, M.A., Chaiffetz, D., Fitzgerald, M.G., Devera, M.E., and Fontes, P. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant. 2011; 11: 1287–1295
CrossRef | PubMed | Scopus (22)

[415]Cuadrado, A., Fabrega, E., Casafont, F., and Pons-Romero, F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005; 11: 420–426
CrossRef | PubMed | Scopus (117)

[416]Rice, J.P. and Lucey, M.R. Should length of sobriety be a major determinant in liver transplant selection?. Curr Opin Organ Transplant. 2013; 18: 259–264
CrossRef | PubMed | Scopus (6)

[417]Dumortier, J., Guillaud, O., Adham, M., Boucaud, C., Delafosse, B., Bouffard, Y. et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol. 2007; 102: 1032–1041
CrossRef | PubMed | Scopus (38)

[418]Tandon, P., Goodman, K.J., Ma, M.M., Wong, W.W., Mason, A.L., Meeberg, G. et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol. 2009; 104: 1700–1706
CrossRef | PubMed | Scopus (38)

[419]Patil, D.T. and Yerian, L.M. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl. 2012; 18: 1147–1153
CrossRef | PubMed | Scopus (13)

[420]Watt, K.D. and Charlton, M.R. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010; 53: 199–206
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[421]Wang, X., Li, J., Riaz, D.R., Shi, G., Liu, C., and Dai, Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12: 394–402 (e1)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[422]El-Masry, M., Puig, C.A., and Saab, S. Recurrence of non-viral liver disease after orthotopic liver transplantation. Liver Int. 2011; 31: 291–302
CrossRef | PubMed | Scopus (14)

[423]Graziadei, I.W. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002; 8: 575–581
CrossRef | PubMed | Scopus (87)

[424]Graziadei, I.W. Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased?. Curr Opin Gastroenterol. 2011; 27: 301–305
CrossRef | PubMed | Scopus (9)

[425]Matter, M.S., Decaens, T., Andersen, J.B., and Thorgeirsson, S.S. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014; 60: 855–865
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[426]Chen, K., Man, K., Metselaar, H.J., Janssen, H.L., Peppelenbosch, M.P., and Pan, Q. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl. 2014; 20: 261–269
CrossRef | PubMed | Scopus (7)

[427]Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378–390
CrossRef | PubMed | Scopus (3869)

[428]Sposito, C., Mariani, L., Germini, A., Flores Reyes, M., Bongini, M., Grossi, G. et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol. 2013; 59: 59–66
Abstract | Full Text | Full Text PDF | PubMed | Scopus (24)

[429]Yoon, D.H., Ryoo, B.Y., Ryu, M.H., Lee, S.G., Hwang, S., Suh, D.J. et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol. 2010; 40: 768–773
CrossRef | PubMed | Scopus (38)

[430]Gonwa, T.A., Mai, M.L., Melton, L.B., Hays, S.R., Goldstein, R.M., Levy, M.F. et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001; 72: 1934–1939
CrossRef | PubMed

[431]Gonwa, T.A., McBride, M.A., Anderson, K., Mai, M.L., Wadei, H., and Ahsan, N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?. Am J Transplant. 2006; 6: 2651–2659
CrossRef | PubMed | Scopus (152)

[432]Rodriguez-Peralvarez, M., Germani, G., Darius, T., Lerut, J., Tsochatzis, E., and Burroughs, A.K. Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy. Am J Transplant. 2013; 13: 239
CrossRef | PubMed | Scopus (2)

[433]Gavalda, J., Vidal, E., and Lumbreras, C. Infection prevention in solid organ transplantation. Enferm Infecc Microbiol Clin. 2012; 30: 27–33
CrossRef | PubMed | Scopus (0)

[434]Karuthu, S. and Blumberg, E.A. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012; 7: 2058–2070
CrossRef | PubMed

[435]Safdar, N., Said, A., Lucey, M.R., Knechtle, S.J., D’Alessandro, A., Musat, A. et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis. 2004; 39: 517–525
CrossRef | PubMed | Scopus (19)

[436]Kotton, C.N., Kumar, D., Caliendo, A.M., Asberg, A., Chou, S., Danziger-Isakov, L. et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013; 96: 333–360
CrossRef | PubMed | Scopus (90)

[437]Lucey, M.R., Terrault, N., Ojo, L., Hay, J.E., Neuberger, J., Blumberg, E. et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013; 19: 3–26
CrossRef | PubMed | Scopus (63)

[438]Burra, P., Buda, A., Livi, U., Rigotti, P., Zanus, G., Calabrese, F. et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. Eur J Gastroenterol Hepatol. 2006; 18: 1065–1070
CrossRef | PubMed | Scopus (23)

[439]Allen, U. and Preiksaitis, J. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009; 9: S87–S96
CrossRef | PubMed | Scopus (57)

[440]Singh, N., Wagener, M.M., Marino, I.R., and Gayowski, T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation. 2002; 73: 63–67
CrossRef | PubMed

[441]Osawa, M., Ito, Y., Hirai, T., Isozumi, R., Takakura, S., Fujimoto, Y. et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl. 2007; 13: 566–570
CrossRef | PubMed | Scopus (18)

[442]Patel, R., Portela, D., Badley, A.D., Harmsen, W.S., Larson-Keller, J.J., Ilstrup, D.M. et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996; 62: 926–934
CrossRef | PubMed | Scopus (148)

[443]Eschenauer, G.A., Lam, S.W., and Carver, P.L. Antifungal prophylaxis in liver transplant recipients. Liver Transpl. 2009; 15: 842–858
CrossRef | PubMed | Scopus (31)

[444]Martin, S.I. and Fishman, J.A. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009; 9: S227–S233
CrossRef | PubMed | Scopus (54)

[445]Torre-Cisneros, J., Doblas, A., Aguado, J.M., San Juan, R., Blanes, M., Montejo, M. et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis. 2009; 48: 1657–1665
CrossRef | PubMed | Scopus (84)

[446]Munoz, P., Rodriguez, C., and Bouza, E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005; 40: 581–587
CrossRef | PubMed | Scopus (151)

[447]Yehia, B.R. and Blumberg, E.A. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl. 2010; 16: 1129–1135
CrossRef | PubMed | Scopus (19)

[448]Madhwal, S., Atreja, A., Albeldawi, M., Lopez, R., Post, A., and Costa, M.A. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl. 2012; 18: 1140–1146
CrossRef | PubMed | Scopus (19)

[449]Desai, S., Hong, J.C., and Saab, S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int. 2010; 30: 948–957
CrossRef | PubMed | Scopus (26)

[450]Watt, K.D., Pedersen, R.A., Kremers, W.K., Heimbach, J.K., Sanchez, W., and Gores, G.J. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009; 137: 2010–2017
Abstract | Full Text | Full Text PDF | PubMed | Scopus (67)

[451]Guichelaar, M.M., Schmoll, J., Malinchoc, M., and Hay, J.E. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology. 2007; 46: 1198–1207
CrossRef | PubMed | Scopus (46)

[452]Millonig, G., Graziadei, I.W., Eichler, D., Pfeiffer, K.P., Finkenstedt, G., Muehllechner, P. et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005; 11: 960–966
CrossRef | PubMed | Scopus (55)

[453]Leidig-Bruckner, G., Hosch, S., Dodidou, P., Ritschel, D., Conradt, C., Klose, C. et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001; 357: 342–347
Abstract | Full Text | Full Text PDF | PubMed | Scopus (176)

[454]Monegal, A., Navasa, M., Guanabens, N., Peris, P., Pons, F., Martinez de Osaba, M.J. et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001; 12: 484–492
CrossRef | PubMed | Scopus (100)

[455]Sethi, A. and Stravitz, R.T. Review article: medical management of the liver transplant recipient - a primer for non-transplant doctors. Aliment Pharmacol Ther. 2007; 25: 229–245
CrossRef | PubMed | Scopus (18)

[456]Engels, E.A., Pfeiffer, R.M., Fraumeni, J.F. Jr., Kasiske, B.L., Israni, A.K., Snyder, J.J. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011; 306: 1891–1901
CrossRef | PubMed | Scopus (226)

[457]Finkenstedt, A., Graziadei, I.W., Oberaigner, W., Hilbe, W., Nachbaur, K., Mark, W. et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009; 9: 2355–2361
CrossRef | PubMed | Scopus (45)

[458]Penn, I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg. 1996; 2: 52–59
CrossRef | PubMed

[459]Euvrard, S., Kanitakis, J., and Claudy, A. Skin cancers after organ transplantation. N Engl J Med. 2003; 348: 1681–1691
CrossRef | PubMed | Scopus (754)

[460]Herrero, J.I., Espana, A., Quiroga, J., Sangro, B., Pardo, F., Alvarez-Cienfuegos, J. et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005; 11: 1100–1106
CrossRef | PubMed | Scopus (51)

[461]Chak, E. and Saab, S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int. 2010; 30: 1247–1258
CrossRef | PubMed | Scopus (41)

[462]Herrero, J.I., Pardo, F., D’Avola, D., Alegre, F., Rotellar, F., Inarrairaegui, M. et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl. 2011; 17: 402–408
CrossRef | PubMed | Scopus (27)

[463]Chandok, N. and Watt, K.D. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012; 18: 1277–1289
CrossRef | PubMed | Scopus (27)

[464]Bergner, M. Quality of life, health status, and clinical research. Med Care. 1989; 27: S148–S156
CrossRef | PubMed

[465]Wilson, I.B. and Cleary, P.D. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995; 273: 59–65
CrossRef | PubMed

[466]Kanwal, F., Hays, R.D., Kilbourne, A.M., Dulai, G.S., and Gralnek, I.M. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease?. Am J Gastroenterol. 2004; 99: 1726–1732
CrossRef | PubMed | Scopus (52)

[467]Testa, M.A. and Simonson, D.C. Assesment of quality-of-life outcomes. N Engl J Med. 1996; 334: 835–840
CrossRef | PubMed | Scopus (1324)

[468]Jay, C.L., Butt, Z., Ladner, D.P., Skaro, A.I., and Abecassis, M.M. A review of quality of life instruments used in liver transplantation. J Hepatol. 2009; 51: 949–959
Abstract | Full Text | Full Text PDF | PubMed | Scopus (36)

[469]Bona, M.D., Rupolo, G., Ponton, P., Iemmolo, R.M., Boccagni, P., Destro, C. et al. The effect of recurrence of HCV infection of life after liver transplantation. Transpl Int. 1998; 11: S475–S479
CrossRef | PubMed

[470]De Bona, M., Ponton, P., Ermani, M., Iemmolo, R.M., Feltrin, A., Boccagni, P. et al. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. J Hepatol. 2000; 33: 609–615
CrossRef | PubMed

[471]Cowling, T., Jennings, L.W., Goldstein, R.M., Sanchez, E.Q., Chinnakotla, S., Klintmalm, G.B. et al. Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol-related transplant recipients. Ann Surg. 2004; 239: 93–98
CrossRef | PubMed | Scopus (28)

[472]Ruppert, K., Kuo, S., DiMartini, A., and Balan, V. In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosis. Gastroenterology. 2010; 139: 1619–1629 (29 e1–e4)
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[473]Desai, R., Jamieson, N.V., Gimson, A.E., Watson, C.J., Gibbs, P., Bradley, J.A. et al. Quality of life up to 30 years following liver transplantation. Liver Transpl. 2008; 14: 1473–1479
CrossRef | PubMed | Scopus (40)

[474]Burra, P., De Martin, E., Gitto, S., and Villa, E. Influence of age and gender before and after liver transplantation. Liver Transpl. 2013; 19: 122–134
CrossRef | PubMed | Scopus (10)

[475]Cowling, T., Jennings, L.W., Goldstein, R.M., Sanchez, E.Q., Chinnakotla, S., Klintmalm, G.B. et al. Liver transplantation and health-related quality of life: scoring differences between men and women. Liver Transpl. 2004; 10: 88–96
CrossRef | PubMed | Scopus (33)

[476]Bunzel, B. and Laederach-Hofmann, K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation. 2000; 70: 711–716
CrossRef | PubMed

[477]McDonald, H.P., Garg, A.X., and Haynes, R.B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002; 288: 2868–2879
CrossRef | PubMed | Scopus (670)

[478]Osterberg, L. and Blaschke, T. Adherence to medication. N Engl J Med. 2005; 353: 487–497
CrossRef | PubMed | Scopus (2988)

[479]Sabate, E. Adherence to long-term therapies: evidence for action. World Health Organization (WHO), Geneva, Switzerland; 2003

[480]Dew, M.A., DiMartini, A.F., De Vito, Dabbs A., Myaskovsky, L., Steel, J., Unruh, M. et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007; 83: 858–873
CrossRef | PubMed | Scopus (151)

[481]Cramer, J., Rosenheck, R., Kirk, G., Krol, W., and Krystal, J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003; 6: 566–573
Abstract | Full Text PDF | PubMed | Scopus (100)

[482]Rodriguez, A., Diaz, M., Colon, A., and Santiago-Delpin, E.A. Psychosocial profile of noncompliant transplant patients. Transplant Proc. 1991; 23: 1807–1809
PubMed

[483]Germani, G., Lazzaro, S., Gnoato, F., Senzolo, M., Borella, V., Rupolo, G. et al. Nonadherent behaviors after solid organ transplantation. Transplant Proc. 2011; 43: 318–323
Abstract | Full Text | Full Text PDF | PubMed | Scopus (17)

[484]Burra, P., Germani, G., Gnoato, F., Lazzaro, S., Russo, F.P., Cillo, U. et al. Adherence in liver transplant recipients. Liver Transpl. 2011; 17: 760–770
CrossRef | PubMed | Scopus (30)

[485]Burra, P. The adolescent and liver transplantation. J Hepatol. 2012; 56: 714–722
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1)

[486]Gilmour, S., Adkins, R., Liddell, G.A., Jhangri, G., and Robertson, C.M. Assessment of psychoeducational outcomes after pediatric liver transplant. Am J Transplant. 2009; 9: 294–300
CrossRef | PubMed | Scopus (29)

[487]Sorensen, L.G., Neighbors, K., Martz, K., Zelko, F., Bucuvalas, J.C., and Alonso, E.M. Cognitive and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results. Am J Transplant. 2011; 11: 303–311
CrossRef | PubMed | Scopus (31)

[488]Fredericks, E.M., Magee, J.C., Opipari-Arrigan, L., Shieck, V., Well, A., and Lopez, M.J. Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr Transplant. 2008; 12: 289–299
CrossRef | PubMed | Scopus (57)

[489]Gilmour, S.M., Sorensen, L.G., Anand, R., Yin, W., and Alonso, E.M. School outcomes in children registered in the studies for pediatric liver transplant (SPLIT) consortium. Liver Transpl. 2010; 16: 1041–1048
CrossRef | PubMed | Scopus (20)

[490]Shemesh, E. Beyond graft survival and into the classroom: should school performance become a new posttransplant outcome measure?. Liver Transpl. 2010; 16: 1013–1015
CrossRef | PubMed | Scopus (0)

[491]Bownik, H. and Saab, S. Health-related quality of life after liver transplantation for adult recipients. Liver Transpl. 2009; 15: S42–S49
CrossRef | PubMed | Scopus (33)

[492]Aberg, F., Hockerstedt, K., Roine, R.P., Sintonen, H., and Isoniemi, H. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant. 2012; 26: 729–735
CrossRef | PubMed | Scopus (10)

[493]Huda, A., Newcomer, R., Harrington, C., Blegen, M.G., and Keeffe, E.B. High rate of unemployment after liver transplantation: analysis of the United Network for Organ Sharing database. Liver Transpl. 2012; 18: 89–99
CrossRef | PubMed | Scopus (3)

[494]Burra, P., Germani, G., Masier, A., De Martin, E., Gambato, M., Salonia, A. et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?. Transplantation. 2010; 89: 1425–1429
CrossRef | PubMed | Scopus (18)

[495]Bravata, D.M., Olkin, I., Barnato, A.E., Keeffe, E.B., and Owens, D.K. Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg. 1999; 5: 318–331
CrossRef | PubMed

[496]Ho, J.K., Ko, H.H., Schaeffer, D.F., Erb, S.R., Wong, C., Buczkowski, A.K. et al. Sexual health after orthotopic liver transplantation. Liver Transpl. 2006; 12: 1478–1484
CrossRef | PubMed | Scopus (32)

[497]Sorrell, J.H. and Brown, J.R. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl. 2006; 12: 1473–1477
CrossRef | PubMed | Scopus (32)

[498]Huyghe, E., Kamar, N., Wagner, F., Yeung, S.J., Capietto, A.H., El-Kahwaji, L. et al. Erectile dysfunction in liver transplant patients. Am J Transplant. 2008; 8: 2580–2589
CrossRef | PubMed | Scopus (11)

[499]Burra, P. Sexual dysfunction after liver transplantation. Liver Transpl. 2009; 15: S50–S56
CrossRef | PubMed | Scopus (10)

[500]Johnson, E.M., Zimmerman, J., Duderstadt, K., Chambers, J., Sorenson, A.L., Granger, D.K. et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc. 1996; 28: 987
PubMed

[501]Lee, S., Coco, M., Greenstein, S.M., Schechner, R.S., Tellis, V.A., and Glicklich, D.G. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant. 2005; 19: 162–167
CrossRef | PubMed | Scopus (35)

[502]Mass, K., Quint, E.H., Punch, M.R., and Merion, R.M. Gynecological and reproductive function after liver transplantation. Transplantation. 1996; 62: 476–479
CrossRef | PubMed

[503]McKay, D.B., Josephson, M.A., Armenti, V.T., August, P., Coscia, L.A., Davis, C.L. et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005; 5: 1592–1599
CrossRef | PubMed | Scopus (155)

[504]<http://www.fda.gov>.[505]Robinson, L.R., Switala, J., Tarter, R.E., and Nicholas, J.J. Functional outcome after liver transplantation: a preliminary report. Arch Phys Med Rehabil. 1990; 71: 426–427
http://www.fda.gov | PubMed

[506]Beyer, N., Aadahl, M., Strange, B., Kirkegaard, P., Hansen, B.A., Mohr, T. et al. Improved physical performance after orthotopic liver transplantation. Liver Transpl Surg. 1999; 5: 301–309
CrossRef | PubMed

[507]Krasnoff, J.B., Vintro, A.Q., Ascher, N.L., Bass, N.M., Paul, S.M., Dodd, M.J. et al. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant. 2006; 6: 1896–1905
CrossRef | PubMed | Scopus (38)

[508]Painter, P., Krasnoff, J., Paul, S.M., and Ascher, N.L. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl. 2001; 7: 213–219
CrossRef | PubMed | Scopus (72)

[509]Roske, A.E. and Plauth, M. Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient?. Nutrition. 1999; 15: 504–505
Abstract | Full Text PDF | PubMed | Scopus (4)

[510]Kallwitz, E.R. Metabolic syndrome after liver transplantation: preventable illness or common consequence?. World J Gastroenterol. 2012; 18: 3627–3634
CrossRef | PubMed | Scopus (13)

[511]Didsbury, M., McGee, R.G., Tong, A., Craig, J.C., Chapman, J.R., Chadban, S. et al. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation. 2013; 95: 679–687
CrossRef | PubMed | Scopus (17)

[512]Richards, J., Gunson, B., Johnson, J., and Neuberger, J. Weight gain and obesity after liver transplantation. Transpl Int. 2005; 18: 461–466
CrossRef | PubMed | Scopus (75)

[513]Fishman, J.A. and Grossi, P.A. Donor-derived infection–the challenge for transplant safety. Nat Rev Nephrol. 2014; 10: 663–672
CrossRef | PubMed | Scopus (1)